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FDG-PET SCANS IN STAGE III NSCLC PATIENTS UNDERGOING DEFINTIVE RADIATION 
THERAPY 
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  The purpose of this work was to determine if quantitative image features (QIFs) extracted 
from computed tomography (CT) and flourodeoxyglucose (FDG) positron emission tomography 
(PET) could provide prognostic information to improve outcome models. Our goal for this work was 
to determine if it may one day be feasible to incorporate QIFs into personalized cancer care. QIFs 
were used to quantitatively characterize patient disease as seen on imaging.  A leave-one-out cross-
validation procedure was used to assess the prognostic ability of QIFs extracted from CT and PET in 
addition to conventional prognostic factors (CPFs).  QIFs were found to improve model fit for overall 
survival in contrast enhanced CT (CE-CT) (p = 0.027) and FDG-PET (p = 0.007). 
Correlations/associations were observed between QIFs from CE-CT, FDG-PET, and CPFs. However, 
our results indicate that while correlations/associations exist, QIFs provided additional prognostic 
information. QIFs from FDG-PET improved models using CPFs including GTV in terms of patient 
stratification, c-index, and log-likelihood more than QIFs from CE-CT alone. Various studies were 
performed assessing the reproducibility of FDG-PET based QIFs and found that reconstruction 
methods certainly impact the obtained QIF values. However, features maintain a reasonable 
reproducibility (mean CCC = 0.78) that may be improved when using similar reconstructions (e.g., 
3D OSEM) (CCC = 0.93).  The two FDG-PET features found to be prognostic were also able to 
isolate sub-cohorts of patients that demonstrated survival differences based on radiation dose. 
QIFs were found to provide additional prognostic information beyond that found from CPFs. 
Initial evidence suggests that the examined FDG-PET based QIFs may have utility across cohorts and 
could potentially determine which patients may benefit from dose escalation. 
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Chapter 1 Introduction 
Non-small cell lung cancer (NSCLC) results in more deaths than any other type of cancer in 
the United States.1 AJCC TNM staging, which classifies patients as stage I through IV, is a 
commonly used tool that dictates patient prognosis and treatment.2 Patients with stages I-III are 
viewed as potentially curative and receive definitive treatment.  Early stage patients (stages I/II) can 
achieve a 5-year survival rate between 45-50% and are predominantly treated with surgical resection.3  
Locally-advanced, non-metastatic (stage III) patients have a 5-year survival rate between 5-15%.3  
These patients are predominantly treated with a combination of radiation therapy and chemotherapy 
(chemoradiotherapy).  Stage III NSCLC is a particularly diverse cohort because patients can have 
varying primary tumor size/extent (T stages: 1 through 4) and nodal involvement (N stages: 0 through 
3).  This diversity of patients yields similarly diverse outcomes.  Some patients succumb to their 
disease only a few months after diagnosis while others are able to do remarkably well and live 5 or 
more years post treatment.   
Currently, the predominant factor in assessing prognosis and treatment is the patient’s TNM 
stage. Further individualization is performed in practice based on other conventional prognostic 
factors (CPFs), such as tumor volume, histology, age, gender, performance status, and smoking 
history.4 However, the impact of these CPFs is based purely on the experience/opinion of the treating 
physician(s) and is not standardized.  Furthermore, quantitative models have been shown to have the 
ability to outperform physicians when it comes to predicting a patient’s outcome to treatment.5 While 
there is a body of literature regarding CPFs in stage III NSCLC, there are no standardized tools that 
allow physicians to individually predict patient outcome in order to give a more personalized 
prognosis or aid in treatment decision making. Outcome nomograms exist for various other forms of 
cancer via the Memorial Sloan Kettering Cancer Center (http://www.mskcc.org/nomograms).  
However, these nomograms are not routinely used in the clinic, have yielded a wide range of 
observed results, and only utilize relatively generic CPFs similar to TNM staging.   
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The concept of personalized cancer care recognizes that each cancer patient is unique. The 
needs, tolerances, and outcomes of patients can vary widely even if they receive the same 
treatment/care and are classified as similar based on CPFs. Therefore, a major goal in cancer 
medicine is to eventually tailor each patient’s care specifically to that individual rather than to utilize 
population-based data when determining prognosis, appropriate follow-up intervals, or treatment.6, 7  
Medical imaging is a source of potentially prognostic information that is routinely obtained, 
non-invasive, and specific to each patient. Imaging is already a primary tool for determining TNM 
stage and is currently performed as part of routine standard of care for patients with NSCLC. 
Additionally, there is a growing body of evidence suggesting that additional prognostic information 
can be ascertained from quantitatively analyzing a patient’s tumor using quantitative image features 
(QIFs). QIFs are commonly based on disease histograms, co-occurrence matrices, nearest gray tone 
difference matrices, filtration-based features, and shape/volume based features.8–11 These QIFs have 
been shown to have prognostic abilities in a variety of settings using pretreatment computed 
tomography (CT) and fluorodeoxyglucose (FDG) positron emission tomography (PET) scans.8, 10, 12–25 
This process is referred to as “radiomics” since it was motivated by other high-throughput analyses 
methods, such as genomics, proteomics, etc. However, many radiomics studies relate QIFs purely to 
patient outcome and not any sort of genomic, proteomic, or biological endpoint.   
Multiple publications using QIFs extracted from CT scans have shown relationships between 
tumor heterogeneity and patient outcome.8, 10, 14–17, 19, 20, 25–30 Relationships have been observed using 
both non-contrast enhanced (NCE) and contrast enhanced (CE) scans. Furthermore, associations have 
also been shown relating QIFs from CT to tumor histology, genetic variations, and glucose 
metabolism. The largest and most comprehensive of these studies was performed by Aerts et al.8 
They found that a four-feature signature developed from a cohort of 422 patients had prognostic 
power when applied to an independent data set of 225 patients.  They also were able to demonstrate 
associations between the four prognostic QIFs and tumor gene expression in a cohort of 83 patients.  
All of these cohorts consisted of patients with NSCLC of varying stages (i.e., stages I through IV). 
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Other literature regarding prognostic value of CT-based QIFs is largely composed of small, 
retrospective studies that frequently utilize re-substitution statistics or optimal cut-off methods for 
assessing prognostic value. Proper validation techniques are needed when analyzing the potential 
impact of CT-based QIFs. Ideally, bootstrapping or cross-validation techniques may be utilized if 
independent or external sources of data are not available. Furthermore, there is tremendous 
uncertainty in the literature regarding whether information from CT-based QIFs yields added 
predictive accuracy compared to CPFs, such as staging, disease volume, performance status, 
histology, etc.   
Similar observations and pitfalls exist regarding FDG-PET-based QIFs. A significant body of 
literature exists regarding “standard” FDG-PET measures, such as SUVmax, SUVmean, metabolic tumor 
volume, etc.31–34 However, significantly fewer publications address more complex QIFs examining 
disease heterogeneity and shape. The literature regarding more complex QIFs is composed 
predominantly of small, retrospective studies lacking proper validation and/or multivariate analyses 
examining the added benefit of QIFs to currently known CPFs. Nonetheless, existing publications 
suggests a potential relationship between FDG-PET-based QIFs and patient outcome in NSCLC.12, 21, 
35, 36 
While there is compelling evidence that additional prognostic information can be extracted 
from quantitatively analyzing CT and FDG-PET, additional evaluations are needed to thoroughly 
investigate the potential of QIFs in these modalities and to address gaps in existing data. The goal of 
this work is to expand upon findings from existing publications regarding CT and FDG-PET QIFs in 
an effort establish a foundation for assessing whether or not imaging-based QIFs may one day be 
used as part of personalized cancer care. Retrospective cohorts will be generated and used to extract 
QIFs from patient imaging alongside patients CPF and outcomes from patient medical records. This 
data will be used to assess the prognostic value of QIFs and CPFs, variability/reproducibility of QIFs, 
and to quantify the relationship(s) between QIFs, CPFs, and physical tumor characteristics (e.g., 
19 
 
necrosis, vessels, and cavitation).  Exploratory analysis will evaluate the possible modification of 
treatment based on QIFs.   
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Chapter 2 Principal Hypothesis and Specific Aims 
Principal Hypothesis:  
The addition of quantitative image features from CT and PET scans to models using only 
conventional prognostic factors can improve patient outcome models.  
 
Specific Aim 1: Analysis of CT-based Quantitative Image Features 
Specific Aim 1 Hypothesis: The addition of CT-based quantitative image features will significantly 
improve outcome models compared to models using conventional prognostic factors 
Project 1.1 Quantify the impact of adding CT-based quantitative image features to outcome 
models containing only CPFs including and excluding GTV 
Project 1.2 Quantify the reproducibility of CT-based quantitative image features and its impact 
on outcome models 
Project 1.3 Quantify the prognostic value of adding CE-CT-based quantitative image features to 
outcome models containing only CPFs 
 
Specific Aim 2: Analysis of FDG-PET-based Quantitative Image Features 
Specific Aim 2 Hypothesis: The addition of FDG-PET-based quantitative image features will 
significantly improve outcome models compared to models using conventional prognostic factors 
Project 2.1 Quantify the impact of adding FDG-PET-based quantitative image features to 
outcome models containing only CPFs 
Project 2.2 Quantify the reproducibility of FDG-PET-based quantitative image features using 
“pseudo” test-retest scans 
Project 2.3 Quantify the reproducibility of FDG-PET-based quantitative image features using 
retrospective reconstructions of phantom and patient data  
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Specific Aim 3: Assess relationships between CT-based quantitative image features, PET-based 
quantitative image features, conventional features, and morphologic features 
Specific Aim 3 Hypothesis: There will be significant relationships between some quantitative image 
features between modalities and with tumor volume, staging, and morphologic characteristics.  
Project 3.1 Quantify correlations between prognostic FDG-PET-based and CECT-based 
quantitative image features 
Project 3.2 Quantify if relationships exist between CE-CT-based and FDG-PET-based 
quantitative image features with tumor volume and TNM staging 
Project 3.3 Quantify if there are correlations between FDG-PET-based quantitative image 
features, CECT-based quantitative image features, and morphologic characteristics (vessels, 
necrosis, air cavities, etc.) 
 
Specific Aim 4: Potential use of FDG-PET-based quantitative image features 
Specific Aim 4 Hypothesis: Significant FDG-PET-based based quantitative image features found in 
Specific Aim 2 will allow for identification of sub-cohorts that will demonstrate a significant 
stratification of patients based on radiation dose.  
Project 4.1 Assess whether significant PET-based quantitative image features relate to a 
difference in patient survival for those treated with an escalated radiation dose   
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Chapter 3 Methodology 
A substantial portion of the methods is written or based on the following publications: 
Fried DV, Mawlawi O, Zhang L, Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of 
FDG PET quantitative image features combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published 
online July 15, 2015. ©Radiological Society of North America. 
 
Fried DV, Tucker SL, Zhou S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture 
Features in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 
10.1016/j.ijrobp.2014.07.020. Volume 90, Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
The permissions for reuse of these materials were obtained from both the Radiological Society of North America and Elsevier B V.  
 
3.1 Conventional Prognostic Factors 
We extracted patient T stage (T1/T2 vs T3/T4), N stage (N0/N1 vs N2/N3), Overall Stage (3a 
vs 3b), age, gender, histology (squamous cell carcinoma vs other), Karnofsky performance status 
(KPS) (100-90 vs <90), smoking status (current, former, never), estimated pack years, use of 
induction chemotherapy, and gross tumor volume (GTV) from the medical record.  These factors 
were included as they have all been suggested to be prognostic in stage III NSCLC.4  All TNM 
staging was performed according to the 7th edition American Joint Committee on Cancer staging 
manual.37  GTV consisted of both the primary and nodal disease as defined by the treating radiation 
oncologist for definitive radiation therapy. The GTV was transformed in all cohorts except Cohort 1 
(the different cohorts are descried below) prior to modeling using the logarithm to the base 2 in order 
to reduce the influence of relatively extreme measurements during the modeling process. The GTV in 
Cohort 1 was not log transformed as the distribution of GTV was relatively free of outliers and was 
approximately normally distributed. CPFs were used to construct reference prediction models using 
factors previously thought to be prognostic in stage III NSCLC in order to have an appropriate 
assessment for the incremental benefit of QIFs. It is essential in biomarker research to demonstrate 
evidence that new biomarkers (i.e., QIFs) provide added prognostic value in addition to what is 
already known from CPFs. There is some debate regarding whether to treat GTV as a CPF or QIF. 
While GTV is quantitative in nature and not considered part of determining AJCC TNM stage, it has 
been cited as a prognostic factor in NSCLC in a variety of publications. To accommodate both sides 
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of this debate, results using CPFs excluding GTV, CPFs including GTV, and CPFs including GTV 
and QIFs were determined. 
3.2 Patient Cohorts 
Cohort 1: 91 Patients with Pretreatment Tavg, T50, and CE-CT  
 We retrospectively reviewed the medical records of patients with stage III NSCLC treated at 
MD Anderson Cancer Center with definitive radiation therapy between July 2004 and January 2012. 
These dates were chosen in order to include patients receiving 4DCT, which our institution 
implemented in early 2004, and provide adequate follow-up time.  We excluded all patients receiving 
induction chemotherapy, proton-based radiation therapy, <5 years post-treatment for another solid 
tumor, multiple primary lesions, non-platinum-based concurrent chemotherapy, and those not 
receiving a diagnostic contrast-enhanced scan prior to 4DCT treatment planning. The median follow-
up for all living patients at time of analysis was 59 months (range, 17 – 97 months).  CPFs and 
treatment characteristics of all patients are listed in Table 1. All patients received a diagnostic 
contrast-enhanced CT (CE-CT) and a non-contrasted 4DCT scan prior to treatment. For contrast-
enhanced scans, patients were scanned using 120 kVp, 400-1160 mA, and an exposure time of 265-
570 ms. All images were reconstructed using the standard reconstruction kernel. Axial images were 
512 x 512 pixels with voxel dimensions of 0.059-0.090 cm x 0.059-0.090 cm x 0.25 cm. For the 
4DCT scans, the average intensity projection (TAVG) and expiratory phase (T50) images were used in 
this study. Patients were scanned using 120 kVp, 100-200 mA, and an exposure time of 500-800 ms.  
All images were reconstructed using the standard reconstruction kernel.  Axial images were 512 x 
512 pixels with voxel dimensions of 0.096 cm x 0.096 cm x 0.25-0.30 cm. 
Effort was made to generate a cohort that was as homogeneous as possible in terms of their 
clinical characteristics (all stage III NSCLC), treatment characteristics (all treated with definitive 
radiation therapy), and imaging characteristics (similar acquisition/reconstruction parameters). 
The aim of this cohort was to test the improvement of using QIFs from CT in outcome models 
compared to models using only CPFs. 
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Table 1. Cohort 1 – Patient CPFs and Treatment Characteristics 
Conventional Prognostic 
Factors 
N % 
Treatment 
Characteristics 
N % 
No. Patients 91 NA Radiation Dose   
Median Age (years) 65 NA 1.8- 2.0 Gy/fx 79 87 
Mean GTV (cc) 132 NA Other 12 13 
Gender   Radiation Type   
Male 55 60 3DCRT 5 6 
Female 36 40 IMRT 86 94 
T Stage   Concurrent Chemotherapy   
T1/T2 43 47 Carboplatin-based 78 86 
T3/T4 48 53 Cisplatin-based 13 14 
N Stage   Adjuvant Chemotherapy   
N0/N1 11 12 Yes 37 41 
N2/N3 80 88 No 54 59 
Overall Stage      
IIIa 45 50    
IIIb 46 50    
Histology      
Squamous cell carcinoma 46 50    
Other 45 50    
Smoking Status      
Never 5 6    
Former 65 71    
Current 21 23    
Pack Years      
0-24 13 14    
25-49 37 41    
50-74 22 24    
75+ 19 21    
Performance Status 
(KPS) 
     
100-90 37 41    
80-70 53 58    
<70 1 1    
Abbreviations: No. = Number; cc = cubic centimeters; GTV = gross tumor volume; KPS = Karnofsky performance status; 
Gy = gray; fx = fraction; 3DCRT = 3 dimensional conformal radiation therapy; IMRT = intensity modulated radiation 
therapy 
 
This table has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker 
SL, Zhou S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture 
Features in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 
10.1016/j.ijrobp.2014.07.020. Volume 90, Issue 4, Pages 834-842. 2014. ©Elsevier. 
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Cohort 2: 249 Patients with Pretreatment CE-CT  
 We retrospectively reviewed the medical records of patients with stage III NSCLC treated 
with definitive radiation therapy between August 2004 and December 2012.  These dates were chosen 
in order to include many patients receiving contrast-enhanced CT scans during the time of use of 
4DCT at MD Anderson Cancer Center and provide adequate follow-up time.  We excluded all 
patients <5 years post-treatment for another solid tumor, multiple primary lesions and those not 
receiving a diagnostic contrast-enhanced scan prior treatment.  These criteria yielded a cohort of 249 
patients for analysis.  The median follow-up for all patients living at the time of analysis was 53 
months (range, 15 – 106 months).  CPFs and treatment characteristics of all patients are listed in 
Table 2.   All patients received a diagnostic contrast-enhanced CT (CE-CT) and a non-contrasted 
4DCT scan prior to treatment.  For contrast-enhanced scans, patients were scanned using 120 kVp, 
400-1160 mA, and an exposure time of 265-570 ms.  All images were reconstructed using the 
standard reconstruction kernel.  Axial images were 512 x 512 pixels with voxel dimensions of 0.059-
0.090 cm x 0.059-0.090 cm x 0.25 cm.    
The purpose of this cohort was similar to cohort 1. Effort was made to identify a 
homogeneous cohort of patients in terms of clinical characteristics, treatment characteristics, and 
imaging characteristics. The predominant difference being the increased number of patients (91 
versus 249) and that these were only required to have a pretreatment CE-CT for analysis. We found 
that CE-CT features appeared to be the most prognostic in section 4.1.1 Results for Project 1.1: 
Quantify the impact of adding CT-based quantitative image features to outcome models containing 
only CPFs including and excluding GTV. Therefore, this cohort was assembled to test if a model 
could be developed using only CE-CT derived features and test whether using QIFs from CE-CT 
improved outcome models compared to models using only CPFs.  
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Table 2. Cohort 2 - Patient CPFs and Treatment Characteristics 
Conventional Prognostic 
Factors 
N % 
Treatment 
Characteristics 
N % 
No. Patients 249 NA Fractionation   
Median Age (years) 66 NA 1.8- 2.0 Gy/fx 227 91 
Mean GTV (cc) 156 NA Other 22 9 
Gender   Radiation Type   
Male 138 55 3DCRT 9 4 
Female 11 44 IMRT 187 75 
T Stage   Protons 53 21 
T1/T2 145 58 Chemotherapy Sequence   
T3/T4 104 42 Concurrent 105 42 
N Stage   Induction-Concurrent 60 24 
N0/N1 24 10 Concurrent-Adjuvant 69 28 
N2/N3 225 90 Other 8 3 
Overall Stage   None 7 3 
IIIa 131 53 Concurrent Type   
IIIb 118 47 Platin Doublet 212 85 
Histology   Platin Doublet + Erlotinib 13 5 
Squamous Cell Carcinoma 104 42 Single Agent Platin 11 4 
Other 145 58    
Smoking Status      
Never 16 6    
Former 182 74    
Current 51 20    
Pack Years      
0-24 44 18    
25-49 88 35    
50-74 63 25    
75+ 54 22    
Performance Status 
(KPS) 
     
100-90 73 29    
80-70 171 69    
<70 5 2    
Abbreviations: No. = Number; cc = cubic centimeters; GTV = gross tumor volume; KPS = Karnofsky performance status; 
Gy = gray; fx = fraction; 3DCRT = 3 dimensional conformal radiation therapy; IMRT = intensity modulated radiation 
therapy 
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Cohort 3: 195 Patients with Pretreatment PET  
 We retrospectively reviewed the medical records of patients with stage III NSCLC treated 
definitively with external beam radiation therapy between January 2008 and January 2013.  These 
dates were chosen for two reasons: 1) to ensure patients’ PET scans were acquired and reconstructed 
in 3D, which MD Anderson Cancer Center implemented in 2008, and 2) to ensure patients had a 
minimum potential follow-up of one year at the time of analysis.  We excluded patients that were <5 
years post-treatment for another solid tumor, had multiple primary lesions, or had primary lesions 
<5mL as measured on their PET scan.  This yielded 195 patients for analysis.  The median follow-up 
for all patients living at the time of analysis was 37 months (range, 3-70 months).  Three patients 
were lost to follow-up prior to one year. CPFs and treatment characteristics of all patients are listed in 
Table 3.   
All patients received a PET/CT scan prior to initiation of treatment.  Scans were taken using 
either a GE Discovery RX or STE scanner at MD Anderson Cancer Center. Patients with PET scans 
taken at any outside institutions were excluded.  All images were reconstructed using 3D-ordered 
subset expectation maximization using 2 iterations, 20-21 subsets, and a 6mm post-processing 
Gaussian blurring filter.  All images were comprised of 128 x 128 pixels with voxel dimensions of 
5.47 x 5.47 x 3.27 mm.  Patients fasted for at least 6 hours prior to administration of an average 
injected dose of 381 Mbq (range, 255 – 540).  The average duration from injection to scan was 78 
minutes (range, 50 – 124).  A low-dose non-contrasted CT was acquired for attenuation correction 
using 120 kVp, automated mA modulation, 1.35 pitch, and 3.75 mm slice thickness. 
The aim of this cohort was similar to cohorts 1 and 2. We wanted to test the improvement of 
using QIFs from FDG-PET in outcome models compared to models using only CPFs.  
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Table 3. Cohort 3 - Patient CPFs and Treatment Characteristics 
Conventional Prognostic 
Factors 
N % 
Treatment 
Characteristics 
N % 
No. Patients 195 NA Fractionation   
Median Age (years) 66 NA 1.8- 2 Gy/fx 160 82 
Mean GTV (cc) 183 NA Other 35 18 
Gender   Radiation Type   
Male 125 64 3DCRT 1 <1 
Female 70 36 IMRT 126 66 
T Stage   Protons 64 33 
T1/T2 97 50 Chemotherapy Sequence   
T3/T4 98 50 Concurrent 80 41 
N Stage   Induction-Concurrent 56 29 
N0/N1 31 16 Concurrent-Adjuvant 46 23 
N2/N3 164 84 Other 11 6 
Overall Stage   None 2 1 
IIIa 107 55 Concurrent Type   
IIIb 88 45 Platin Doublet 176 90 
Histology   Platin Doublet + Erlotinib 13 7 
Squamous Cell Carcinoma 89 46 Single Agent Platin 6 3 
Other 106 54    
Smoking Status      
Never 19 10    
Former 130 66    
Current 46 24    
Pack Years      
0-24 47 24    
25-49 55 28    
50-74 49 25    
75+ 44 23    
Performance Status 
(KPS) 
     
100-90 58 30    
80-70 131 67    
<70 6 3    
Abbreviations: No. = Number; cc = cubic centimeters; GTV = gross tumor volume; KPS = Karnofsky performance status; 
Gy = gray; fx = fraction; 3DCRT = 3 dimensional conformal radiation therapy; IMRT = intensity modulated radiation 
therapy 
 
This table has been reused with the permission of the original publisher from the following publication:  Fried DV, Mawlawi 
O, Zhang L, Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of FDG 
PET quantitative image features combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. 
Published online July 15, 2015. ©Radiological Society of North America. 
29 
 
Cohort 4: 78 Patients with Pretreatment PET and Contrast-Enhanced CT 
This cohort contained the 78 patients that were included in both Cohorts 2 and 3.  The 
parameters regarding the patient’s scans are thus the same as described in Cohorts 2 and 3.  The 
primary function of this cohort was to compare features extracted from CECT versus PET/CT as well 
as assess auto-segmentation concordance in terms of necrosis volume.  
Cohort 5: 24 Patients with “Large” Tumors on PET 
 This cohort contained 24 patients from Cohort 3 who had primary tumors ranging in size 
between 77 and 309 cc as measured on FDG-PET. The primary tumors of these patients were 
resampled within MIM version 6.2 (MIM Software Inc., Cleveland, OH) using trilinear interpolation. 
After each resampling, the PETedge tool was used to recontour the primary. This was done in an 
effort to determine how robust features were to changing the size of the region of interest (ROI). 
Some findings have indicated that the ROI volume can influence the obtained quantitative values due 
to the nature of some of the feature calculations.(Xenia Fave, unpublished). This approach was 
primarily used to determine how reproducible the mathematical formulas of the underlying features 
were to changes in volume. In addition, we used these resampled tumors in order to determine an 
approximate threshold where QIF reproducibility breaks down in our patients. The aim was to 
establish a cut-off for tumor volumes that are too small to be adequately assessed using our metrics.   
Cohort 6: 53 Patients with “Pseudo” Test/Retest PET  
This cohort contained 53 patients with NSCLC who received a PET/CT at an outside 
institution followed by a PET/CT at MD Anderson Cancer Center. No treatment was delivered to 
these patients between the two scans. There were no requirements regarding treatment, stage, etc., as 
was the case in other cohorts. The average time between scans was 48 days (range: 8 – 111). The 
purpose of this cohort was to analyze the reproducibility of PET-based QIFs by calculating the 
concordance correlation coefficient (CCC) (see 3.7.6 Concordance Correlation Coefficient).  
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3.3 Quantitative Image Features 
3.3.1 Histogram Features 
Histogram features used a first-order histogram that represents a particular region of interest 
by tabulating the number of pixels within a particular value. For QIFs requiring a histogram (standard 
deviation, uniformity, entropy), i.e., CT scans in Hounsfield units (HU), the images are first 
transformed into 8-bit images across the entire hypothetical CT range resulting in 16 HU bins (4096 
HU values/28 = 16 HU bins).  This transformation was done in order to de-noise the image and supply 
a more appropriate bin size for histogram calculations (i.e., not 1 HU per bin). From a histogram, 
metrics, such as the mean, median, variance, entropy, skewness, kurtosis, and uniformity, can be 
calculated. The mean, median, and variance of a distribution are commonplace in 
mathematics/statistics; however, the concepts of entropy, skewness, kurtosis, and uniformity are often 
times less well-known.  Entropy is generally thought of as the associated “randomness.”  We define 
entropy below in equation 1.  
ENTROPY = − ∑ (
𝐻
𝑛
) ∗  log2 (
𝐻
𝑛
) 
𝑯 = ℎ𝑖𝑠𝑡𝑜𝑔𝑟𝑎𝑚, 𝒏 = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 
Skewness is a measure of the asymmetry of the histogram where a positive value is when the 
distribution is skewed towards lower values and negative value is when a distribution is skewed 
towards higher values.  We define skewness below in equation 2.  
 SKEWNESS =
𝐸(𝑥 − 𝜇)3
𝜎3
        
𝐸 = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒, 𝑥 = 𝑣𝑎𝑙𝑢𝑒𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 ℎ𝑖𝑠𝑡𝑜𝑔𝑟𝑎𝑚, 𝜇 = 𝑚𝑒𝑎𝑛, 𝜎 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 
Kurtosis is a measure of the “peakedness” of the histogram where a positive value is when 
the distribution peaks more than the normal distribution and a negative value is when a distribution 
peaks less than the normal distribution.  We define kurtosis below in equation 3.  
KURTOSIS =
𝐸(𝑥 − 𝜇)4
𝜎4
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𝐸 = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒, 𝑥 = 𝑣𝑎𝑙𝑢𝑒𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 ℎ𝑖𝑠𝑡𝑜𝑔𝑟𝑎𝑚, 𝜇 = 𝑚𝑒𝑎𝑛, 𝜎 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 
Uniformity (or Energy as it is referred to in some publications) is a measure of how much 
variation of values is present in the histogram.  A value of 1 means there is only one value within the 
ROI and the smaller the uniformity the more variation in the values within the ROI. We define 
uniformity below in equation 4.  
 UNIFORMITY = ∑ (
𝐻
𝑛
)
2
        
𝑯 = ℎ𝑖𝑠𝑡𝑜𝑔𝑟𝑎𝑚, 𝒏 = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 
The bin width used for histograms was different between CT and PET images.  For CT, the 
features requiring a histogram (entropy and uniformity) used a bin width of 16 HU. For PET, the 
features requiring a histogram used a bin width of 1 SUV (i.e. entropy and uniformity).  The 
remaining PET histogram features used the native floating point SUV values from the ROI (i.e. mean, 
maximum, peak, standard deviation, coefficient of variation).  
 
3.3.2 Co-Occurrence Matrix Features 
Co-occurrence matrix (COM) features were first proposed by Haralick et al. in 1973.9  These 
features expand upon information contained in histograms by also containing information regarding 
the spatial relationships between voxels.  Traditionally, COM features are calculated by generating a 
matrix relating voxel displacement and directions. In this work, a voxel displacement of 1 was always 
used along with averaging across the unique directions (13 in 3D; 4 in 2D).  This allowed the features 
calculated to be non-directional in nature.  Once the average is performed, the COM is normalized by 
the total number of voxels to express the matrix in terms of probabilities rather than raw counts. 
Averaging across the 13 unique 3D directions was used in the analysis of Cohort 1.  Subsequent 
analyses averaged across the 4-unique 2D directions.  This transition was made in order to address the 
concern of non-isocentric displacements that arise when voxel x-y dimensions are not equivalent to 
the slice spacing within an image.    
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ROIs from CT and PET images were normalized prior to COM matrix feature calculation.  In 
CT, the values within the ROI were scaled to 8 bits (256 values) over the standard digital CT 
representation range (4096 values) in the same manner as previously described.  This effectively 
rounded the values within the ROI to the nearest 16 HU.  In PET, images were first scaled to the 
number of gray levels between the minimum and maximum of the tumor SUV using the minimum 
and maximum as the gray level limits.  This effectively rounded the SUV values within the contour to 
the nearest whole number and subtracted the minimum SUV.  For example, a lesion with a minimum 
SUV of 3.2 and a maximum of 17.8 would be first scaled to be comprised of values ranging from 3 to 
18 and then the minimum value (3) subtracted resulting in values from 0 – 15. This allowed for the 
analyses to have a finite number of gray levels and ensure that the new scaled values had a consistent 
relationship to the underlying SUV values (i.e., a difference of one between scaled values represented 
an SUV change of one). This methodology was recommended by Leijenaar et al. as this methodology 
allows for a more meaningful comparison of texture values between images.38 By subtracting the 
minimum SUV value, the COM features were calculated using variability in uptake regardless of 
underlying amplitude.  Other metrics, such as SUVmax and SUVmean, were used to quantify 
amplitude of uptake.  
Numerous COM features exist within the literature.  A variety of these features were 
investigated during the course of multiple projects; however, the four features that were consistently 
used in all analyses are explained below.  COM(i,j) corresponds to the COM for an arbitrary 
displacement and direction.  
COM contrast quantifies the amount of discrepancy in values seen within the ROI. COM 
contrast increases when there are voxels within a displacement region that differ greatly in terms of 
their value (this is expressed in the |i-j|2 term below). 
𝑪𝑶𝑵𝑻𝑹𝑨𝑺𝑻 =  ∑ ∑|𝑖 − 𝑗|2
𝑁
𝑗=1
𝑁
𝑖=1
𝐶𝑂𝑀(𝑖, 𝑗) 
𝑵 = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 
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COM correlation quantifies the joint probability occurrence of the specified pixel pairs (i.e., 
the dependency of values on those of the neighboring pixels). 
𝑪𝑶𝑹𝑹𝑬𝑳𝑨𝑻𝑰𝑶𝑵 = ∑ 𝐶𝑂𝑀(𝑖, 𝑗) [
(𝑖 − 𝜇𝑖)(𝑗 − 𝜇𝑗)
𝜎𝑖2𝜎𝑗2
]
𝑁−1
𝑖,𝑗=0
 
𝝁𝒊 = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝐶𝑂𝑀 𝑟𝑜𝑤𝑠, 𝝁𝒋 = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝐶𝑂𝑀 𝑐𝑜𝑙𝑢𝑚𝑛𝑠 
𝝈𝒊 = variance of COM rows, 𝝈𝒋 = variance of COM columns 
 
COM energy quantifies the variation in values seen within the ROI and is very similar to 
histogram uniformity. The main difference is that COM energy is based on values within the 
specified displacement (1 in this work) whereas in histogram uniformity, location of voxels plays no 
role. If the probability of finding adjacent voxels with different values is high, the COM energy will 
decrease, and if the probability of finding adjacent voxels with similar values or patterns of values is 
low, the COM energy will be closer to 1.  A uniform image has a COM energy value of 1.   
𝑬𝑵𝑬𝑹𝑮𝒀 = ∑ ∑ 𝐶𝑂𝑀(𝑖, 𝑗)2
𝑁
𝑗=1
𝑁
𝑖=1
 
𝑵 = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 
COM homogeneity quantifies how consistent values are within the ROI. This can also be 
seen as the opposite of contrast only with a linear relationship between value differences rather than 
an exponential one.   
𝑯𝑶𝑴𝑶𝑮𝑬𝑵𝑬𝑰𝑻𝒀 =  ∑ ∑
𝐶𝑂𝑀(𝑖, 𝑗)
1 + |𝑖 − 𝑗|
𝑁
𝑗=1
𝑁
𝑖=1
 
 Additional COM features were only assessed in section 4.1 Results of Specific Aim 1. The 
formulas for these features are shown below.  
𝑺𝑼𝑴 𝑶𝑭 𝑺𝑸𝑼𝑨𝑹𝑬𝑺: 𝑽𝑨𝑹𝑰𝑨𝑵𝑪𝑬 =  ∑ ∑(𝑖 − 𝜇)2
𝑁
𝑗=1
𝑁
𝑖=1
𝐶𝑂𝑀(𝑖, 𝑗) 
𝜇 = 𝑀𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 
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𝑰𝑵𝑽𝑬𝑹𝑺𝑬 𝑫𝑰𝑭𝑭𝑬𝑹𝑬𝑵𝑪𝑬 𝑴𝑶𝑴𝑬𝑵𝑻 =  ∑ ∑
1
1 + (𝑖 − 𝑗)2
𝑁
𝑗=1
𝑁
𝑖=1
 𝐶𝑂𝑀(𝑖, 𝑗) 
𝑺𝑼𝑴 𝑨𝑽𝑬𝑹𝑨𝑮𝑬 =  ∑ 𝑖𝑝𝑥+𝑦(𝑖)
𝑁
𝑖=2
𝐶𝑂𝑀(𝑖, 𝑗) 
𝑝𝑥+𝑦(𝑖) = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑐𝑜 − 𝑜𝑐𝑐𝑢𝑟𝑒𝑛𝑐𝑒 𝑚𝑎𝑡𝑟𝑖𝑥 𝑐𝑜𝑟𝑟𝑑𝑖𝑛𝑎𝑡𝑒𝑠 𝑠𝑢𝑚𝑖𝑛𝑔 𝑡𝑜 𝑥 + 𝑦 
𝑺𝑼𝑴 𝑽𝑨𝑹𝑰𝑨𝑵𝑪𝑬 =  ∑(𝑖 − 𝑆𝑈𝑀 𝐸𝑁𝑇𝑅𝑂𝑃𝑌)2𝑝𝑥+𝑦(𝑖)
𝑁
𝑖=2
 
𝑺𝑼𝑴 𝑬𝑵𝑻𝑹𝑶𝑷𝒀 =  − ∑ 𝑝𝑥+𝑦(𝑖)
𝑁
𝑖=2
𝐿𝑂𝐺{𝑝𝑥+𝑦(𝑖)} 
𝑬𝑵𝑻𝑹𝑶𝑷𝒀 = −  ∑ ∑ 𝐶𝑂𝑀(𝑖, 𝑗)
𝑁
𝑗=1
𝑁
𝑖=1
𝐿𝑂𝐺{𝐶𝑂𝑀(𝑖, 𝑗)} 
𝑫𝑰𝑭𝑭𝑬𝑹𝑬𝑵𝑪𝑬 𝑬𝑵𝑻𝑹𝑶𝑷𝒀 =  − ∑ 𝑝𝑥−𝑦(𝑖)𝐿𝑂𝐺{
𝑁−1
𝑖=0
𝑝𝑥−𝑦(𝑖)} 
𝑝𝑥−𝑦(𝑖) = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑐𝑜 − 𝑜𝑐𝑐𝑢𝑟𝑒𝑛𝑐𝑒 𝑚𝑎𝑡𝑟𝑖𝑥 𝑐𝑜𝑟𝑟𝑑𝑖𝑛𝑎𝑡𝑒𝑠 𝑠𝑢𝑚𝑖𝑛𝑔 𝑡𝑜 𝑥 − 𝑦 
𝑰𝑵𝑭𝑶𝑹𝑴𝑨𝑻𝑰𝑶𝑵 𝑴𝑬𝑨𝑺𝑼𝑹𝑬 𝑶𝑭 𝑪𝑶𝑹𝑹𝑬𝑳𝑨𝑻𝑰𝑶𝑵 𝟏 =  
𝐻𝑋𝑌 − 𝐻𝑋𝑌1
𝑀𝐴𝑋(𝐻𝑋, 𝐻𝑌)
 
𝐻𝑋𝑌 = 𝐸𝑁𝑇𝑅𝑂𝑃𝑌; 𝐻𝑋 𝑎𝑛𝑑 𝐻𝑌 = 𝑒𝑛𝑡𝑟𝑜𝑝𝑦𝑖𝑒𝑠 𝑜𝑓 𝑝𝑥 𝑎𝑛𝑑 𝑝𝑦 
𝐻𝑋𝑌1 =  −  ∑ ∑ 𝐶𝑂𝑀(𝑖, 𝑗)
𝑁
𝑗=1
𝑁
𝑖=1
𝐿𝑂𝐺{𝑝𝑥(𝑖)𝑝𝑦(𝑗)} 
𝐻𝑋𝑌2 =  −  ∑ ∑ 𝑝𝑥(𝑖)𝑝𝑦(𝑗)
𝑁
𝑗=1
𝑁
𝑖=1
𝐿𝑂𝐺{𝑝𝑥(𝑖)𝑝𝑦(𝑗)} 
𝑰𝑵𝑭𝑶𝑹𝑴𝑨𝑻𝑰𝑶𝑵 𝑴𝑬𝑨𝑺𝑼𝑹𝑬 𝑶𝑭 𝑪𝑶𝑹𝑹𝑬𝑳𝑨𝑻𝑰𝑶𝑵 𝟐 = 1 − 𝑒√−2(𝐻𝑋𝑌2−𝐻𝑋𝑌) 
 
 
 
 
35 
 
3.3.3 Nearest Gray Tone Difference Features 
Nearest gray tone difference features were introduced by Amadasum and King.11  Their aim 
was to design texture features corresponding to visual properties due to their wide applicability and 
promise in feature selection. We calculated these features after converting CT scans into 8-bit images 
in the same manner as described above in section 3.3.2 Co-Occurrence Matrix Features. These 
features are calculated by first constructing a 1-D matrix (NGTDM) where “the ith entry is a 
summation of the differences between the gray level of all pixels with gray level I, and the average 
gray level of their surrounding neighbors.” Four features were extracted from this matrix: coarseness, 
contrast, busyness, and complexity using a neighborhood distance of 1 in all three dimensions.  
 Coarseness measures the size of the primitive (basic pattern) making up the texture. For 
instance, an image of static would have a small coarseness value; however, a checkerboard with large 
square sizes would have a large coarseness value.   
𝐶𝑂𝐴𝑅𝑆𝐸𝑁𝐸𝑆𝑆 = [𝜖 + ∑ 𝑝𝑖𝑠(𝑖)
𝐺ℎ
𝑖=0
]
−1
 
 𝒑𝒊 = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑜𝑐𝑐𝑢𝑟𝑒𝑛𝑐𝑒 𝑜𝑓 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 (𝑖), 𝒔(𝒊) =  𝑖𝑡ℎ 𝑒𝑛𝑡𝑟𝑦 𝑖𝑛 𝑁𝐺𝑇𝐷𝑀,   
𝝐 = 1𝐸 − 6, 𝑮𝒉 = ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 
 
Contrast is a measure of visible of different intensity levels within the ROI.  For instance, an 
image of black and white stripes has adjacent regions of high and low values and thus has very high 
contrast.   
𝐶𝑂𝑁𝑇𝑅𝐴𝑆𝑇 = [
1
𝑁𝑔(𝑁𝑔 − 1)
∑ ∑ 𝑝𝑖𝑝𝑗(𝑖 − 𝑗)
2
𝐺ℎ
𝑖=0
𝐺ℎ
𝑗=0
] [
1
𝑁𝑔2
∑ 𝑠(𝑖)
𝐺ℎ
𝑖=0
] 
𝒑𝒊/𝒋 = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑜𝑐𝑐𝑢𝑟𝑒𝑛𝑐𝑒 𝑜𝑓 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 (𝑖/𝑗), 𝒔(𝒊) =  𝑖𝑡ℎ 𝑒𝑛𝑡𝑟𝑦 𝑖𝑛 𝑁𝐺𝑇𝐷𝑀,   
 𝑵𝒈 = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒𝑠, 𝑮𝒉 = ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 
 
Busyness measures the amount of rapid changes of intensity from pixel to its neighbor (i.e., 
the spatial frequency of intensity changes).   
𝐵𝑈𝑆𝑌𝑁𝐸𝑆𝑆 =
[∑ 𝑝𝑖𝑠(𝑖)
𝐺ℎ
𝑖=0 ]
∑ ∑ 𝑖𝑝𝑖 − 𝑗𝑝𝑗
𝐺ℎ
𝑖=0
𝐺ℎ
𝑗=0
⁄  
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𝒑𝒊/𝒋 = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑜𝑐𝑐𝑢𝑟𝑒𝑛𝑐𝑒 𝑜𝑓 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 (𝑖/𝑗), 𝒔(𝒊) =  𝑖𝑡ℎ 𝑒𝑛𝑡𝑟𝑦 𝑖𝑛 𝑁𝐺𝑇𝐷𝑀,  
𝑮𝒉 = ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 
 
Complexity measures the information content within an ROI.  ROIs with many primitives 
with varying average intensities are viewed to have high content and thus high complexity. 
∑ ∑ [
|𝑖 − 𝑗|
𝑛2(𝑝𝑖 + 𝑝𝑗)
]
𝐺ℎ
𝑗=0
𝐺ℎ
𝑖=0
[𝑝𝑖𝑠(𝑖) + 𝑝𝑗𝑠(𝑗)] 
 
𝒑𝒊/𝒋 = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑜𝑐𝑐𝑢𝑟𝑒𝑛𝑐𝑒 𝑜𝑓 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 (𝑖/𝑗), 𝒔(𝒊) =  𝑖𝑡ℎ 𝑒𝑛𝑡𝑟𝑦 𝑖𝑛 𝑁𝐺𝑇𝐷𝑀,  
𝑮𝒉 = ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑔𝑟𝑎𝑦 − 𝑡𝑜𝑛𝑒 
 
3.3.4 Laplacian of Gaussian Filtration Features 
Laplacian of Gaussian filtration (LOG) features rely on the Laplacian of Gaussian filter, 
which is commonly used for edge and/or blob detection. An LOG filter first convolves a given image 
with a Gaussian kernel with a specified scale (σ) and then the result is computed with a Laplacian 
operator. The scales examined were 1, 1.5, 1.8, 2.0 and 2.5. These scales along with a filter size of 
11-voxels were chosen as they have been used extensively in publications by Ganeshan et al.10, 14, 15, 19 
Since the voxels within our images were approximately 1mm in the x-y dimension, edges/objects 
larger than approximately 4mm (σ = 1) to 12mm (σ = 2.5) were not blurred out by the Gaussian 
portion of the LOG filter. This allowed the selection of a particular scale by which to blur out 
potential image noise and selectively focus on areas of interest of differing sizes (e.g. regions of 
heterogeneity between 4 and 12mm). A filter size of 11-voxels was used as this was found to be 
sufficient to include the entirety of the filter at the various scales yet an increase in this size did not 
drastically alter the quantified feature values. Modifications to a pure LOG filtering process need to 
be made when applying this filter to a ROI and not an entire image.  The steps used in our work are 
described below: 
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1. A threshold is applied to the original ROI to exclude values below -50HU (i.e., air). These 
values are replaced with the value 5000 (or arbitrary “high” number in relation to the HU 
values within the image). This is done to remove edge effects later in the calculation.   
2. The LOG kernel is applied to each 2D slice with the designated σ with a size of 11x11. 
3. The result is converted into an unsigned integer so that all negative values are converted to 
zeros. The replacement of values with 5000 in Step 1 is performed so that influences of the 
edge of the ROI are negative values and are thus removed.   
Once these steps are performed, the resulting filtered image is used to calculate the average, 
standard deviation, entropy, and uniformity of the results. An example of the result can be seen in 
Figure 1. It can be seen that the filtered image highlights the edges seen within the original image but 
does not take into consideration the edge of the air cavity within the center of the tumor.  It can also 
be seen that the “tissue” in the superior portion of the tumor has a larger number and more intense 
edges than the necrotic fluid present under the air cavity. The edges seen within the necrotic fluid are 
most likely due to noise from the reconstruction while the more intense edges in the tumor tissue are 
most likely due to vessel and tissue contrast enhancement.  
 
Figure 1. Laplacian of Gaussian Example. Original Tumor (left) and Results of LOG 
Filtration (right) (σ = 1) 
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3.3.5 Contrast Enhanced CT Auto-segmentation of Morphologic Characteristics 
We developed an auto-segmentation algorithm to separate tumors into air, necrosis, tissue, 
and enhancing vessels components (see Figure 2). Physician-delineated gross tumor volumes (GTV) 
were drawn from patients’ treatment CTs (non-contrasted). The GTV contour was transferred to the 
diagnostic CE-CT after deformable registration of the two images. The cutoffs used within the auto-
segmentation algorithms were defined by taking manually drawn regions of interest from 10+ 
patients. Tumor tissue, enhancing vessels, and necrosis were delineated and used to determine 
histograms for each tissue type. Values that maximally separated the histograms from each tissue type 
were used as cutoffs. The auto-segmentation allows for the calculation of the volume of each category 
along with the percentage each category represents of a particular tumor.  The algorithm follows the 
series of steps described below: 
1. Air outside the tumor is removed via thresholding below the value of -50 HU. 
Any portions that are removed but are surrounded by non-excluded voxels are filled with the 
value of 0 HU. The voxels are filled to minimize the impact of air in the following step 
(blurring).  
2. The resulting region of interest (ROI) is blurred with a Gaussian kernel of size 5x5 pixels and 
a sigma of 1.5. The blurring leads to more accurate thresholding segmentation that is less 
influenced by image noise.  
3. An initial guess of what regions constitute necrosis is made by finding voxels with values 
between -25 HU and 20 HU. Values surrounded by voxels deemed to be part of the initial 
necrosis guess are also deemed part of the initial necrosis guess. 
(Steps 4-9 deal exclusively with identifying necrosis). 
4. The initial necrosis guess is then eroded two pixels and dilated two pixels. The purpose of 
this is to remove small regions. 
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5. If a necrotic guess does not exist, then the tumor is deemed to have no voxels that constitute 
necrosis, and the algorithm proceeds to Step 10. If a necrotic guess does exist, the algorithm 
continues to Step 6. 
6. The largest 3D continuous region of the initial necrosis guess is identified and the centroid 
found. 
7. From this centroid, a 3D region growing algorithm is performed using an inclusion criterion 
of being within ±35HU of the initial centroid seed point. 
8. Post region growing, 2D regions containing less than 50 pixels are removed. This is done to 
avoid small regions of necrosis that are not usually observed (i.e., a vast majority of necrotic 
regions are quite sizable). 
9. The resulting voxels are deemed “necrosis.” 
10. Regions having values less than -50Hu are deemed “air.” 
11. Voxels with values greater than 120HU are the initial enhancing vessel guess. Regions that 
are less than 3 voxels are removed and the result is deemed “enhancing vessels”. 
12. Voxels with values between 20 HU and 120 HU are the initial tissue guess.  Regions smaller 
than 20 voxels are removed from the guess. 
13. Regions belonging to air, necrosis, or enhancing vessels are removed from the tissue guess. 
14. The results are deemed “tissue.” Unlabeled regions can exist; however, these regions are 
usually located at a tumor/air border and have a very small volume.  
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Figure 2. CE-CT Results of Auto-segmentation of Air (gray), Necrosis (red), Tissue (green), 
and Vessels (blue) 
 
This auto-segmentation allows for the calculation of the volume of each category along with 
the percentage each category represents of a particular tumor.   
 
3.3.6 PET Necrosis Auto-segmentation 
The PET necrosis auto-segmentation algorithm first must have an ROI that encompasses the 
tumor. These contours were first made using the PETedge tool in MIMvista as described in previous 
work.39  The algorithm then follows the series of steps below: 
1. Voxels within 5 voxels of the edge vertically or horizontally or 3 voxels diagonally are 
deemed not eligible to be labeled as necrosis. 
2. If no voxels are eligible or the max SUV within the eligible voxels is less than 8, the tumor is 
designated to not have any necrosis.  Otherwise, proceed to Step 3. The value of 8 was used 
as it was observed during algorithm development that necrotic regions rarely had SUV values 
higher than 8. 
3. A k-means clustering is performed with the number of means equal to one-fifth the range of 
the eligible voxels plus one.  The lowest k-means centroid from this process is used as the 
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threshold for necrosis unless this value is greater than an SUV of 5.  If the threshold from the 
k-means process is greater than 5, then 5 is used as the guess.  The purpose of this is to adjust 
the level of the threshold based on the range of the SUV values within the tumor. Tumors 
with lower overall SUV values tend to also have lower SUV within necrotic regions.  This 
adaptive step helps to facilitate picking a representative cutoff.  
4. The voxels that are eligible and greater than the threshold cutoff are deemed not necrosis 
while the remaining values are still eligible. 
5. The voxels still eligible to be deemed necrotic are then eroded using the same process as 
described in Step 1.  
6. Remaining eligible voxels are removed if they are not at least connected to two other voxels 
(i.e., the minimum size criteria for a necrotic region is 3 voxels). 
7. Voxels that remain eligible after these steps are deemed necrotic. 
 
An example of the result of this process is shown below in Figure 3. 
 
Figure 3. PET Results of Auto-segmentation of Necrosis (blue) 
 
This auto-segmentation allows for the calculation of the volume of necrosis and the 
percentage of the tumor that is necrotic. The segmentation of necrosis is simpler on FDG-PET than on 
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CE-CT due to its functional nature and higher contrast between necrotic and non-necrotic tissue. The 
volume of necrosis and the percentage of the tumor that is necrotic were compared between 
autosegmentation methods as a measure of robustness of the CE-CT segmentation.   
3.4 Region of Interest Contouring on CT 
Tumor texture analysis on CT scans was conducted using the primary gross tumor volume (GTV) 
contour delineated by each patient’s treating physician.  The nodal tumor volumes were excluded 
from texture analysis.  In some cases, further contour modification was performed.  The reason for 
further modification is due to the goal of analyzing tissue with an extremely high likelihood of 
representing tumor, whereas clinically physicians routinely include any and all tissue with a 
reasonable likelihood of representing tumor.  Therefore, overly generous portions of the contour, 
such as invasion into bone and other normal tissue structures such as the aorta, were modified.  
Contours were extracted and analyzed directly from the treatment planning system using in-house 
software (IBEX) developed by Luke Hunter and Dr. Lifei Zhang built using a commercial software 
package (Matlab version 8.1.0. Natick, Massachusetts: The MathWorks Inc., 2013).40, 41  For the 
AVG-CT and T50-CT, a lower and upper threshold of -100 to 200 HU was implemented to exclude 
lung tissue, air, and/or bone in order to determine our final ROI.  A lower threshold of -100 HU was 
used for the contrast enhanced images in Cohort 1 and -50 HU threshold in subsequent cohorts. In 
CE-CT images, no upper threshold was used.  Only voxels within the defined threshold bounds were 
included in the texture analysis. 
3.5 Region of Interest Contouring on PET 
Patient’s primary and nodal tumor volumes were delineated using the PETedge feature from 
MIM version 6.2 (MIM Software Inc., Cleveland, OH). This method was chosen as it was found to be 
the most accurate and consistent technique for target volume contouring for lung cancer lesions on 
FDG-PET in an extensive review by Werner-Wasik et al.42 This study found that PETedge was the 
most accurate for both segmenting spheres at multiple source-to-background ratios and multiple sizes. 
Spheres of a known volume that were > 20mm and < 20mm in diameter were found to have lower 
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mean absolute percent error (10.99% error) using PET edge compared to thresholding (17.5% error) 
(25% to 50% at 5% increments of SUVmax) and manual segmentation (19.5% error). It was also 
observed that PETedge had the least systematic bias (-0.05% error) among the segmentation methods 
tested. PETedge works, in principal, by first placing the cursor towards the center of the lesion of 
interest. Upon clicking, four “spokes” emanate from the central point in orthogonal directions and 
dragging the cursor extends them until they reach what the user identifies as a reasonable edge of the 
tumor. The software then uses the gradient of the SUV values to determine where the maximum 
descent is located and contours accordingly. This algorithm is purely quantitative and is therefore not 
influenced by the user’s preference of window/level, which can generate significant variation in the 
apparent size of the lesion. For heterogeneous and/or necrotic tumors, this sequence sometimes had to 
be repeated more than once to adequately cover the entire tumor. The PETedge algorithm is semi-
automated and thus is capable of higher throughput than manual contouring. When contouring the 
primary and nodal volumes on the FDG-PET, the radiation treatment plan and the diagnostic 
radiology notes were consulted to determine location of primary and nodal disease. Once the contours 
were finished, they were exported along with the FDG-PET image into IBEX. 
One issue that arose during this process was that the RT structure is stored as a series of 
spatial points based on a resolution higher than that of PET scans. IBEX is programmed to convert 
these line/point contours into binary masks for analysis. IBEX considers any voxel containing or 
within the contour as part of the binary mask. This was problematic for the voxels at the edge of the 
contour due to the relatively low-resolution of PET.  The issue initially observed was that voxels 
could be included in the binary mask when the majority of the voxel was not even within the contour.  
In order to remedy this, Dr. Lifei Zhang and I developed a resampling algorithm that determined the 
fraction of the edge PET voxels that were included in the delineated contour.  This was then used to 
determine how much of the voxel should be included in the contour in order to be analyzed (i.e., 
included in the binary mask). The results of this process can be seen in Figure 4. For this work, a 50% 
cutoff was used to determine which voxels would be analyzed (i.e., if a majority of the voxel was 
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inside the contour, it was analyzed). This algorithm helped ensure that unnecessary low SUV voxels 
from the tumor edge were not included in the analyses. 
 
 
Figure 4. (A) Original FDG-PET Contour/Image (B) Analyzed Voxels Using a 50% Cutoff 
 
3.6 Assessment of QIF Reproducibility using Phantom and Patient Data 
A National Electrical manufacturers Assocation (NEMA) International Electrotechnical 
Commision (IEC) PET phantom was used to assess the reproducibility of QIFs on 3 different 
scanners (GE Discovery VCT, GE Discovery 710, and Siemens mCT). Phantom preparation and 
initial scanning was performed by Dr. Osama Mawlawi and Joe Meier. Acquisitions were made using 
a source-to-background ratio of approximately 10:1. The phantom contains 6 spheres with inner 
diameters of 10, 13, 17, 22, 28 and 37mm suspended in the background of 18F-FDG water. The 
phantom was positioned at the center of the FOV of the PET scanner and data were acquired in 3D 
mode. Acquisitions lengths were varied in an effort to provide equal integrated disintegrations (i.e. 
count statistics). Initial acquisitions were made on three PET scanners (GE Discovery VCT, GE 
Discovery 710, and Siemens mCT) using standard clinical protocols by Dr. Osama Mawlawi and Joe 
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Meier. I then retrospectively reconstructed using different values of iteration, subsets, Gaussian filter 
width, and matrix size. Table 4 below illustrates the reconstructions acquired per scanner. These 
values were chosen as the seemed representative of what was performed clinically in a publication 
analyzing PET/CT scanner performance characterization.43  The differences in parameters between 
scanners (i.e., 21 versus 24 subsets) were due to differences in manufacturer options. Both the 710 
and mCT were reconstructed using time-of-flight whereas the VCT was not as it is not time-of-flight 
capable.  
Table 4. Parameters Used for  Phantom and Patient Retrospective Reconstructions  
GE Discovery VCT GE Discovery 710 Siemens mCT 
Iter SS FW Matrix Size Iter SS FW Matrix Size Iter SS FW Matrix Size 
2 21 2 128 2 24 2 128 2 21 2 128 
2 21 2 256 2 24 4 128 2 21 4 128 
2 21 4 128 2 24 6 128 2 21 6 128 
2 21 4 256 2 24 2 192 2 21 2 200 
2 21 6 128 2 24 4 192 2 21 4 200 
2 21 6 256 2 24 6 192 2 21 6 200 
3 21 2 128 2 24 2 256 2 21 2 256 
3 21 2 256 2 24 4 256 2 21 4 256 
3 21 4 128 2 24 6 256 2 21 6 256 
3 21 4 256 3 24 2 128 3 21 2 128 
3 21 6 128 3 24 4 128 3 21 4 128 
3 21 6 256 3 24 6 128 3 21 6 128 
    3 24 2 192 3 21 2 200 
    3 24 4 192 3 21 4 200 
    3 24 6 192 3 21 6 200 
    3 24 2 256 3 21 2 256 
    3 24 4 256 3 21 4 256 
    3 24 6 256 3 21 6 256 
       Iter = iterations, SS = subsets, FW = filter width 
The image slice going through the center of the spheres was used for analysis. Since the 
spheres were of different sizes, each sphere was impacted to a different degree by partial volume 
effects. Therefore, the SUV values within each of the spheres were not consistent. We exploited this 
observation and proceeded to use these spheres (all at 10:1 source to background) as a surrogate for 
assessing stability of heterogeneous values that are seen in patient tumors.  
We first analyzed all images for each scanner (VCT, 710, mCT) that used a fixed matrix size 
(e.g., 128, 192, 200, or 256). This led to image groupings of 6 images of consistent matrix sizes and 
therefore voxel sizes. These image groups were able to be assessed in a voxel-by-voxel manner since 
these images able to be perfectly overlaid on another. A “range image” could then be produced where 
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the image showed the size of the SUV range within a particular voxel across all six analyzed images 
that used various iterations, subsets, and filter widths within the reconstruction. For example, a 
particular voxel within one of the spheres had values of 1.1, 1.4, 0.9, 2.1, 1.7, and 1.0 in the 6 images 
obtained from a single scanner at a particular matrix size. That voxel in the range image would have a 
value of 1.2 (max value: 2.1 – minimum value: 0.9). An example of a range image is shown below in 
Figure 5. From these range images, we could calculate what percentage of voxels within the spheres 
had a maximum SUV less than 1.  This cutoff was chosen because in our analyses the bin size when 
calculating our QIFs was set to 1. Therefore, voxel changes <1 would not influence the resulting 
feature value more than what is observed by discretizing the image into integer bins from a floating 
point number (SUV) initially.  
 
Figure 5. Example Range Image of NEMA IEC Phantom 
 
Additionally, we calculated QIF values using values within the spheres. We used a threshold 
(SUV > 1.5) on the clinical protocol image (or image closest to what is performed clinically) in order 
to define the contour of the six spheres. This contour was used within each scanner as the input mask 
for calculating the QIFs. The purpose of this segmentation methodology was to ensure that the same 
 
 
80 100 120 140 160 180 200
80
100
120
140
160
180
0
1
2
3
4
5
6
7
8
9
47 
 
contour was being assessed across the different images in order to demonstrate that the changes in 
QIFs were due to the changes in values and not changes in contouring. QIF values were extracted 
from each of the three scanners using the various reconstruction parameters. The median, mean, and 
standard deviation seen within each scanner and across all scanners were calculated and compared to 
the values from the patient data in terms of their standard deviations (Table 13).   
A similar process was performed using patient scans. We identified 5 patients (with 6 
analyzed lesions) with NSCLC with primary tumors that were similar to those included in Cohort 3. 
In terms of volume, these 6 tumors reasonable spanned the range of volumes seen in Cohort 3 (16cc – 
275cc). These patient scans were reconstructed using the same parameters as the phantom scans and 
described in Table 4. However, the primary was re-contoured separately for each reconstruction 
whereas in the phantom analysis the same contour was used for the six spheres across all 
reconstructions for a given matrix size.  
 
3.7 Statistical Methods 
3.7.1 Use of Cross-Validation for Assessment of Prognostic Value 
All statistical analyses were conducted in R 3.0.2 with the following R packages: survival 
v(2.37-4), penalized (0.9-42), and survcomp v(1.10.0).  The CPFs and QIFs (features calculated for 
primary, nodal, and total disease were defined as separate features) extracted from each patient’s 
pretreatment CT or PET scan were entered into a penalized multivariate Cox proportional hazards 
model.  The Cox proportional hazards model is a survival model relating a unit increase in a covariate 
to the hazard rate (i.e., risk of event per unit time).  The hazard function for the proportional hazards 
model is shown below. 
ℎ(𝑡|𝑋) = ℎ(𝑡) exp(𝑋1𝛽1 + ⋯ + 𝑋𝑝𝛽𝑝) 
𝒉(𝒕) = 𝑢𝑛𝑑𝑒𝑟𝑙𝑦𝑖𝑛𝑔 ℎ𝑎𝑧𝑎𝑟𝑑, 𝒉(𝒕|𝑿) = 𝑢𝑛𝑑𝑒𝑟𝑙𝑦𝑖𝑛𝑔 ℎ𝑎𝑧𝑎𝑟𝑑 𝑎𝑠 𝑎 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
𝑿 = 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒 𝑣𝑎𝑙𝑢𝑒, 𝜷 = 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡, 𝒑 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟𝑠 
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This penalized modeling framework simultaneously carries out covariate selection alongside 
model development. Covariate selection is performed as L1 penalization reduces non-informative 
covariate coefficients to zero. This selection allows the user to input “eligible” covariates with the 
algorithm returning only covariates seeming to have prognostic ability via cross-validation. The 
penalization is directed by the L1 penalty parameter, which balances model fit and model complexity.  
The penalty parameter is determined by maximizing the cross-validated likelihood. The R penalized 
package standardizes all covariates by their unit central L2-norm prior to penalization in order to 
minimize the influence of covariate’s scales.  The model coefficients are subsequently rescaled to 
reflect their original covariate’s magnitudes.  
In order to adjust for the bias associated with training and testing a model on the same 
internal dataset, we predominantly used methodologies suggested by Simon et al. to generate cross-
validated Kaplan-Meier curves.44  This methodology allows a reasonable estimate for out-of-sample 
performance of our models while only using an internal dataset.45  Cross-validated Kaplan-Meier 
curves are generated using model predictions for patients that are derived from models developed 
without the patient’s inclusion in model training.  When performing leave-one-out cross validation, a 
patient is left out of model development and a prediction for this patient is generating using the 
remaining cohort.  The patient who is left out is changed and this process repeated such that each 
observation in the sample has a prediction from when it was not involved in model 
development.  These predictions (we utilized the linear predictor generated during each fold of cross-
validation) are used to stratify patients into risk groups. The linear predictor is defined as the sum of 
each of the model coefficient times the corresponding covariate value of that specific patient.  
Therefore, the higher the linear predictor, the higher the predicted risk. We then used these 
predictions to generate risk groups based on a median cutoff in Cohort 1 due to the low number of 
patients or k-means clusters (see 3.7.5 K-Means Clustering of Predictions).  In addition, we also 
calculated the concordance index (c-index) at multiple time points (see 3.7.3 Concordance Index at 
Multiple Time Points).  
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The outcome of overall survival was of primary interest in the analyses followed by local-
regional control and freedom from distant metastases. The outcomes were measured as the time from 
the initiation of treatment until the corresponding event in months.  Treatment initiation was defined 
as the first cycle of chemotherapy for patients receiving induction chemotherapy or the first day of 
radiation treatment for patients receiving radiotherapy upfront.  Patients not experiencing an event 
were censored at the last known follow-up date.  The MD Anderson Cancer Center Institutional 
Review Board approved all retrospective chart review study and waived the need for informed 
consent. The study complied with all Health Insurance Portability and Accountability Act (HIPAA) 
regulations.  
To develop a model using covariates found to be predictive in cross-validation, QIFs that 
were included in greater than 50% of the folds were used along with the CPFs that were included in 
greater than 50% of folds in the preceding analysis. These nested models were compared using a 
likelihood ratio test to assess for impact of adding QIFs.     
3.7.2 Permutation Test and Impact of Feature Reproducibility on Predictions (Cohort 1) 
In Cohort 1, a permutation test was performed where the patient outcomes were randomly 
permuted with respect the QIFs and CPFs and the original analysis was re-run. This process was 
repeated 200 times in order to determine what proportion of randomly permuted data achieved a log-
rank score greater than our original models (i.e., the p-value). 
Test-retest scans were obtained from 10, 10, and 13 independent patients for the TAVG-CT, 
T50-CT, and CE-CT, respectively. The test-retest scans of the AVG-CT and T50-CT images were 
taken at MD Anderson Cancer Center and on average separated by 27 min (range: 16-47).  CE-CT 
test-retest images from patients within a close time period were not available; therefore, CE scans 
taken outside MD Anderson Cancer Center prior to treatment were obtained and compared to the 
diagnostic CE-CT taken within MD Anderson Cancer Center.  The average separation between these 
scans was 38 days (range: 17-72).  The contours for the test-retest scans were performed by a single 
observer (DF) on separate occasions for the test and retest scans in order to incorporate intra-observer 
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contour variability. The classification reproducibility of our models was calculated incorporating the 
reproducibility seen via the test-retest scans. This was performed by utilizing the mean and standard 
deviation of the differences between the extracted metrics from the test and re-test scans to generate a 
normal distribution.   
We added the values obtained by sampling this normal distribution with the associated mean 
and standard deviation of the differences for each feature to the original features. These values were 
then put through the same cross-validation process as the original feature values to determine how the 
reproducibility would influence the predictions and subsequent classification reproducibility.     
The classification reproducibility is defined as the percent of patients categorized into the 
same group as the original models when incorporating the test-retest variation into the texture 
parameters.  This was done for the models incorporating the QIFs and CPFs. The CPFs were assumed 
to be constant.  
3.7.3 Concordance Index at Multiple Time Points 
 The concordance index or c-index was originally introduced by Harrell et al.46  The purpose 
of this measure was to serve as an analog for area under the receiver operating characteristic curve in 
survival analysis. The c-index is computed by analyzing all eligible combinations of patient pairs 
within a cohort. In order to generate c-indices at multiple time points, restrictions were placed as to 
which patient pairs would be eligible to contribute to the c-index calculation. For example, the c-
index at 6 months only allowed patient pairs whose outcomes differed by at least 6 months.      
3.7.4 Analysis of Relationship between Quantitative Image Features, Conventional Features and 
Morphologic Characteristics 
We used the 249 patients in Cohort 2 for this analysis. When comparing QIFs to conventional 
features, such as staging and volume, the QIF values for conventional feature values above and below 
the median were assessed using a Wilcoxon rank-sum test. When comparing QIFs to morphologic 
characteristics, the 249 tumors were divided into two groups (tissue type present or absent based on 
auto-segmentation methods previously described) and compared by their quantitative feature values. 
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Significant differences between the presence/absence of a particular tissue type of tumors in terms of 
the resulting QIFs values were assessed using a Wilcoxon rank-sum test. 
 Additionally, QIF values from tumors containing a particular tissue type were compared to 
the QIF values from the same  tumors using contours that excluded one or all morphological 
characteristics  (e.g., excluding air and necrosis, excluding air and enhancing vessels, including only 
tissue [i.e., excluding air, necrosis, and enhancing vessels respectively], etc.). QIF values obtained 
from the ROIs that excluded a single or combination of tissues were plotted versus the QIF values 
obtained from the entire tumor ROI in Figure 21. In addition, the plots were stratified for vessels and 
necrosis according to whether the volume of vessels or necrosis was greater than the average across 
all tumors where these tissue types were present. Differences between the values obtained from the 
entire tumor versus the same tumors excluding the tissue type(s) were assessed using a paired 
Wilcoxon signed-rank test. Differences in values of LOG_Average and uniformity between tumors 
with higher than average volume of vessels/necrosis versus lower than average volume of 
vessels/necrosis were assessed using a Wilcoxon rank-sum test. The coefficient of determination (R2) 
was calculated from the linear regression for each of these plots.  
The reproducibility of the values obtained for volume and percentage of tumor containing 
necrosis between CE-CT and FDG-PET auto-segmentation methodologies was assessed using the 
concordance correlation coefficient (CCC).47 
3.7.5 K-Means Clustering of Predictions 
The process of using a cutoff based on optimizing the log-rank statistic, the median, or 
balancing patient numbers in each subgroup is quite common in many publications regarding 
prognostic scores or outcome prediction models. Optimization of the log-rank statistic is not a 
preferred method, since these results are almost always overly optimistic and can be problematic, 
particularly when the number of covariates being analyzed increases. Use of the median to separate 
patients into “high risk” and “low risk” is reasonable but not optimal. This process does not take into 
account the underlying distribution of predictions and frequently groups patients with similar 
52 
 
predictions into different risk groups.  Balancing patient numbers (i.e., generating groups with the 
same number of patients in each category) suffers from the same issue as using a median cutoff. We 
proposed implementing a k-means clustering on the generated predictions in order to generate more 
uniform cohorts. In linear regression models, a calibration curve is often shown, plotting the 
predictions versus the actual values. For survival analyses this is not possible since survival curves 
must be generated from multiple patients and the issue of censoring makes it so not every patient has 
a defined “actual value.” By generating uniform cohorts, the displayed Kaplan-Meier curves are a 
more reflective display of calibration of the model/predictions. In our analyses, we increased the 
number of k-means clusters so long as each risk group contained a significant number of patients.    
3.7.6 Concordance Correlation Coefficient 
The concordance correlation coefficient (CCC) measures reproducibility between two 
covariates. Others have used this metric (or the nearly identical intra-class correlation coefficient) to 
assess the reproducibility of texture features under different acquisition conditions. We used the CCC 
when analyzing the reproducibility when resampling in Cohorts 1 and 5 along with the “pseudo” 
test/retest scans from Cohort 6.  
3.7.7 Analysis of PET Tumor Resampling (Cohort 5) 
Primary tumors in Cohort 5 were resampled to different spatial resolutions using trilinear 
interpolation using MIM 6.2. The resulting images of the primary tumors were re-contoured using the 
PETedge feature after each interpolation and grouped into similarly sized cohorts based on the 
number of voxels present. Voxel groupings consisted of the following approximate voxel sizes: 27 
(range: 18-34), 55 (range: 43-73), 108 (range: 92-138), 226 (range: 171-322), and 488 (range: 369-
641). The features calculated from the resampled ROIs were compared to the features calculated from 
the ROIs at native resolution using the CCC. This was performed in an effort to identify if any 
mathematical biases existed due to the nature of the QIF calculations.   
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3.7.8 Sub-cohorts Based on FDG-PET QIFs to Determine Impact of Dose Escalation  
This analysis was performed on Cohort 3. Patients receiving 60-70 Gy (median: 66 Gy) were 
considered “low dose” while patient receiving 74 Gy were considered “high dose.” Different sub-
cohorts comprised of ranges of both solidity and COM energy were examined to determine if any 
sub-cohorts would demonstrate a survival difference between those receiving low and high doses. 
Sub-cohorts were created allowing different values of solidity and COM energy at five percentile 
thresholds. This was done in order to observe if there existed any pattern regarding the impact of dose 
escalation in regards to our QIFs. A log-rank test was used to determine significance of separation 
between low-dose and high-dose patient Kaplan-Meier curves.  We refer to the sub-cohort chosen 
from examining the trend of increasing COM energy and solidity values as the “high QIFs values 
sub-cohort” and the sub-cohort chosen from examining the trend of decreasing COM energy and 
solidity values as the “low QIFs values sub-cohort.”  The sub-cohort chosen in each analysis was 
done so by balancing the number of events and sample size with the p-value being representative of 
all significant cells.   
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Chapter 4 Results 
A substantial portion of the results is described in or based on following publications: 
Fried DV, Mawlawi O, Zhang L, et al. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative image features 
combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published online July 15, 2015. ©Radiological 
Society of North America. 
 
Fried DV, Tucker SL, Zhou S, et al. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-Small Cell 
Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, Issue 4, 
Pages 834-842. 2014. ©Elsevier. 
 
The permissions for reuse of these materials were obtained from both the Radiological Society of North America and Elsevier B V.  
 
4.1 Results of Specific Aim 1: Analysis of CT-based Quantitative Image Features 
Specific Aim 1 examined CT-based quantitative image features for prognostic value, 
reproducibility, and value of each CT image type in cohort 1.  
4.1.1 Results for Project 1.1: Quantify the impact of adding CT-based quantitative image features to 
outcome models containing only CPFs including and excluding GTV 
Sixty-six QIFs were assessed in each fold of cross-validation.  These features are shown in  
 
 
 
 
 
 
 
 
Table 5.  The predictive Kaplan-Meier curves generated from the cross-validated predictions using 
CPFs excluding GTV, CPFs including GTV, and CPFs including GTV and QIFs are shown.  The p-
values in the lower left of each figure represent the p-value of the associated log-rank test. Figure 6, 
Figure 7, and Figure 8 illustrate the stratification in overall survival using the aforementioned 
covariate combination types.   
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Table 5. Extracted Quantitative Image Features for Cohort 1 
Intensity 
Histogram 
(IHIST)^ 
Absolute 
Gradient 
(Grad)- 
Nearest Gray Tone 
Difference Matrix 
(NGTDM)= 
Co-Occurrence 
Matrix (COM)+ 
Laplacian of 
Gaussian  
Filtration 
Metrics (LoG)* 
Mean 
Variance 
Skewness 
Kurtosis 
Entropy 
Uniformity 
Mean 
Variance 
Skewness 
Kurtosis 
% non-zero 
Coarseness 
Contrast 
Busyness 
Energy 
Contrast 
Correlation 
Sum of Squares 
Inv. Diff. Moment 
Sum Average 
Sum Variance 
Sum Entropy 
Entropy 
Diff. Entropy 
Infomc1 
Infomc2 
Mean 
Uniformity 
Standard 
Deviation 
Entropy 
 
^,- Histograms and gradient images were generated by first converting CT into 8-bit image (i.e. bins of 16 HU)  
=NGTDM were computed using a neighborhood = 1 on the converted 8-bit CT 
+COM were computed on the 8-bit CT. Features were averaged across all 3D directions. 
* Sigma values used for the Laplacian of Gaussian Filter of: 1.0, 1.5, 1.8, 2.0, and 2.5 for the largest axial (LA) 
slice and for the entire tumor with a filter size of 11 voxels.  
This table has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou S,Liao 
Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-Small Cell 
Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, Issue 4, 
Pages 834-842. 2014. ©Elsevier. 
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Figure 6. Overall Survival Comparing High Risk versus Low Risk Patients Using Models 
Incorporating CPFs Excluding GTV. 
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 7. Overall Survival Comparing High Risk versus Low Risk Patients Using Models 
Incorporating CPFs Including GTV.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
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Figure 8. Overall Survival Comparing High Risk versus Low Risk Patients Using Models 
Incorporating CPFs Including GTV and CT-Based QIFs.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 9, Figure 10, and Figure 11 illustrate the stratification in local-regional control. 
 
Figure 9. Local-Regional Control Comparing High Risk versus Low Risk Patients Using 
Models Incorporating CPFs Excluding GTV.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
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Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 10. Local-Regional Control Comparing High Risk versus Low Risk Patients Using 
Models Incorporating CPFs Including GTV.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 11. Local-Regional Control Comparing High Risk versus Low Risk Patients Using 
Models Incorporating CPFs Including GTV And CT-Based QIFs.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
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Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 12, Figure 13, and Figure 14 illustrate the stratification in freedom from distant metastses. 
 
Figure 12. Freedom from Distant Metastases Comparing High Risk versus Low Risk 
Patients Using Models Incorporating CPFs Excluding GTV.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 13. Freedom from Distant Metastases Comparing High Risk versus Low Risk 
Patients Using Models Incorporating CPFs Including GTV.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
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Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
Figure 14. Freedom from Distant Metastases Comparing High Risk versus Low Risk 
Patients Using Models Incorporating CPFs Including GTV And CT-Based Qifs.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
 
 Across all outcomes (overall survival, local-regional control, and freedom from distant 
metastases), stratification was improved by including CT-based QIFs to models using CPFs alone or 
CPFs including GTV. No stratification was significant prior to adding the CT-based QIFs according 
to the log rank test (p > 0.05) and stratifications across all outcomes were significant after including 
CT-based QIFs (p < 0.05).  
 Overall survival stratification was much less compared to other two outcomes that were 
assessed. The separation between high and low risk groups did not appear until after 36 months. At 
this time point, the patient numbers in the high and low risk groups were low (11 and 13, 
respectively). While statistically different, the amplitude of difference between risk groups was small. 
 For both local-regional control and freedom from distant metastases, separation between risk 
groups appeared almost immediately and was much higher in amplitude than what was observed for 
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overall survival. Since models for each outcome were generated independently (i.e. patients modeled 
as being low risk in terms of overall survival were not necessarily the same patients modeled as low 
risk in terms of local-regional control or freedom from distant metastases), one can only infer that the 
QIFs appeared more prognostic for disease failure (locally and distantly) than patient survival.  
  
 
 
 
 
 
 
 
 
 
 
Figure 15, Figure 16, and Figure 17 show the concordance indices for overall survival, local-
regional control, and freedom from distant metastases, respectively using the multiple time point 
methodology described in section 3.7.3 Concordance Index at Multiple Time Points. 
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Figure 15. Concordance Indices for Overall Survival Predictions Using Minimum Outcome 
Differences of 6, 12, 18, and 24 Months.  
 
 
Figure 16. Concordance Indices for Local-Regional Control Predictions Using Minimum 
Outcome Differences Of 6, 12, 18, And 24 Months.  
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Figure 17. Concordance Indices for Freedom from Distant Metastases Predictions Using 
Minimum Outcome Differences of 6, 12, 18, And 24 Months.  
 
For overall survival, local-regional control, and freedom from distant metastases predictions 
generated using CPFs including GTV and QIFs resulted in superior stratification of patients.  
Furthermore, c-indices at every time point were greater for predictions generated using CPFs 
including GTV and QIFs. The inclusion of GTV to the other CPFs resulted in improved c-indices in 
all outcomes but the inclusion of QIFs always resulted in additional improvement. Furthermore, it 
was observed that the c-indices increased with an increasing outcome separation between patients (i.e. 
for later time points). This inherently makes sense since one would hope a model would be able to 
predict patient outcomes more effectively when the outcomes are substantially different (e.g. patient 
survivals of 36 months versus 6 months) rather than close (e.g. patient survivals of 12 months versus 
11 months). Larger increases in c-indices for later time points were seen in models utilizing CT-based 
QIFs.   
Table 6 illustrates the models developed from the cross-validation methodology using CPFs 
including GTV and QIFs. 
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Table 6. Outcome Models for Covariate Combinations in Cohort 1 
Covariate 
OS Model 
 
LRC Model 
 
FFDM Model 
 
CPFs: Coefficient p-value Coefficient p-value Coefficient p-value 
Age  
(65> vs ≤65) 
0.37 0.19 NI - NI - 
ECOG  
(0/1 vs 2) 
0.49 0.1 NI - NI - 
Histology  
(SCC vs Other) 
0.31 0.31 NI - NI - 
Gender  
(Male vs Female) 
-0.2 0.46 NI - -1.34 <0.01 
GTV 0.005 <0.01 NI - 0.002 0.35 
QIFs:       
CE-CT       
LoG _Average 
(LA, σ=1) 
0.45 0.01   0.41 0.03 
LOG_Average 
(σ=1) 
NI - 0.59 <0.01 NI - 
IHIST_kurtosis -0.05 0.13 NI - -0.20 0.02 
NGTDM_busyness NI - NI - 108.7 0.21 
COM_infomc1 NI - NI -   
AVG-CT       
LoG_SD 
(σ=1) 
0.04 0.11 NI - 0.15 <0.01 
LoG_SD 
(LA, σ=1.5) 
NI - NI - 0.056 0.43 
LoG_Uniformity 
(LA, σ=2.5) 
1.56 0.04 NI - NI - 
T50-CT       
GRAD_kurtosis NI - NI - 0.202 <0.01 
LOG_Averageσ 
(LA, σ=1.5) 
-0.29 0.12 NI - NI - 
COM_sosvariance 0.003 0.03 NI - NI - 
LoG_Uniformity 
(LA, σ=1.5) 
NI - -2.3 0.05 NI - 
Abbreviations: NI-not included in model, SCC-squamous cell carcinoma, GTV-gross tumor volume, SD-standard 
deviation, LA-largest axial slice. This table has been reused with the permission of the original publisher from the 
following publication:  Fried DV, Tucker SL, Zhou S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic 
Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-Small Cell Lung Cancer. 
International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 
90, Issue 4, Pages 834-842. 2014. ©Elsevier. 
Across all outcomes, features from the CE-CT (specifically the LOG_Average) appeared to 
be the most consistent and significant QIF. The LOG_Average was significant in both local-regional 
control and freedom from distant metastases (p < 0.01 and 0.03, respectively). For overall survival, 
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the same feature but only used on the largest axial slice was significant (p = 0.01). The 
LOG_Averages calculated on the entire tumor versus the largest axial slice were highly correlated 
(Pearson correlation coefficient = 0.91, p < 0.01) and thus would be unlikely to be selected within the 
same model framework due to the ability of the penalized algorithm to handle covariate collinearity.  
To ensure these results were not due to over fitting or the ratio of the number of features 
being analyzed to the number of patients, a permutation test was performed (see 3.7.2 Permutation 
Test and Impact of Feature Reproducibility on Predictions (Cohort 1)). The log-rank statistic derived 
when outcomes were permuted with respect to the QIFs and CPFs (i.e., random data) was greater than 
the true, non-randomized log-rank statistic in 11/200 (p = 0.055), 0/200 (p < 0.005), and 1/200 (p = 
0.005) for OS, LRC, and FFDM, respectively.  
4.1.2 Results for Project 1.2: Quantify the reproducibility of FDG-PET-based quantitative image 
features using “pseudo” test-retest scans 
Data from test-retest scans from 10, 10, and 13 independent patients for the AVG-CT, T50-
CT, and CE-CT, respectively, were used for our assessment of reproducibility.  We found that 
85%,(56/66), 75%,(50/66), and 23%,(15/66) of texture features had a CCC>0.9 for features generated 
from T50-CT, Average-CT, and CE-CT, respectively. 
Incorporating reproducibility within our models yielded 80.4% (SD=3.7), 78.3 (SD=4.0), and 
78.8% (SD=3.9) classification reproducibility in terms of OS, LRC, and FFDM, respectively.  Figure 
18 illustrates an example iteration where we compared the predicted outcome with reproducibility to 
the original predicted outcome in terms of FFDM and calculate the classification reproducibility.   
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Figure 18. Example from Single Simulation of the Impact of Texture Feature 
Reproducibility on FFDM Estimates. Outcome Prediction from Original Model (X-Axis) 
Compared to Prediction Incorporation of the Variation in QIFs From Test/Retest Scans (Y-
Axis). 
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Tucker SL, Zhou 
S,Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic Value and Reproducibility of Pretreatment CT Texture Features in Stage III Non-
Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, and Physics doi: 10.1016/j.ijrobp.2014.07.020. Volume 90, 
Issue 4, Pages 834-842. 2014. ©Elsevier. 
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4.1.3 Results for Project 1.3: Quantify the prognostic value of adding CE-CT-based quantitative 
image features to outcome models containing only CPFs 
The 249 patients in Cohort 2 were used for analysis of prognostic value of CE-CT QIFs. 
Forty three QIFs were assessed during cross-validation.  These features are shown in Table 7.  
 
Table 7. Extracted Quantitative Image Features for Cohort 2 
Intensity 
Histogram 
(IHIST)* 
Nearest Gray 
Tone 
Difference 
Matrix 
(NGTDM)* 
Co-Occurrence 
Matrix (COM)* 
Laplacian of 
Gaussian  
Filtration 
Metrics 
(LoG)* 
Volume/Morphologic 
Characteristics 
Mean 
Standard 
Deviation 
 
Skewness 
Kurtosis 
Entropy 
Uniformity 
Coarseness 
Contrast 
Busyness 
Complexity 
Energy 
Contrast 
Correlation 
Sum of Squares 
Inv. Diff. Moment 
Sum Average 
Sum Variance 
Sum Entropy 
Entropy 
Diff. Entropy 
Infomc1 
Infomc2 
Mean 
Standard 
Deviation 
 
Volume 
Surface Area 
Air Volume 
Tissue Volume 
Necrosis Volume 
Vessel Volume 
Air Percentage 
Tissue Percentage 
Necrosis Percentage 
Vessel Percentage 
*The same parameters were used as described in Table 5 for each type of extracted QIFs 
The predictive Kaplan-Meier curves generated from the cross-validated predictions using 
CPFs excluding GTV, CPFs including GTV, and CPFs including GTV and QIFs are shown in Figure 
19, Figure 20, Figure 21, respectively.  Three clusters based on k-means were used to stratify patients 
into low, medium, and high risk groups based for overall survival. Local-regional control and 
freedom from distant metastases were investigated; however CE-CT based QIFs did not appear to be 
prognostic for these outcomes. A comparison of the c-indices is seen in Figure 22. 
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Figure 19. Overall Survival Comparing High Risk, Medium Risk, and Low Risk Patients 
Using Models Incorporating CPFs Excluding GTV 
 
 
Figure 20. Overall Survival Comparing High Risk, Medium Risk, and Low Risk Patients 
Using Models Incorporating CPFs Including GTV  
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Figure 21. Overall Survival Comparing High Risk, Medium Risk, and Low Risk Patients 
Using Models Incorporating CPFs Including GTV And CE-CT Based QIFs 
 
The addition of GTV to CPFs improved stratification (Figure 19 versus 20) and the c-indices 
at every time point (Figure 22).  However, the addition of QIFs did not improve stratification nor the 
c-index beyond what was obtained using CPFs including GTV (Figure 21). These results are most 
likely due to the dominant prognostic feature being GTV. Table 8 illustrates the models developed 
using the covariates that were included in greater than 50% of the cross-validation folds. For the 
model using CPFs including GTV and QIFs, the significance of GTV was several orders of 
magnitude lower than any other factor. This was not observed in the analysis of Cohort 1. While 
significant, GTV significance was observed to be on a similar order of magnitude as other features in 
Cohort 1.    
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Figure 22. Concordance Indices for Overall Survival in Cohort 2 (CE-CT QIFs Only) Using 
Minimum Outcome Differences of 6, 12, 18, and 24 Months. 
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Table 8. Outcome Models for Covariate Combinations in Cohort 2 
Covariates 
CPFs 
excluding 
GTV 
p-
value 
CPFs 
including 
GTV 
p-value 
CPFs 
including 
GTV and 
QIFs 
p- 
value 
CPFs:       
Age 
(continuous) 
NI - 0.009 0.32 0.012 0.22 
GTV 
(log2) 
NI - 0.296 <0.01 0.340 <0.01 
Gender 
(Male vs 
Female) 
0.151 0.33 NI - NI - 
Histology 
(SCC vs Other) 
0.138 0.37 NI - NI - 
Induction -0.56 <0.01 -0.400 0.04 -0.39 0.04 
KPS 
(<90 vs ≥90) 
0.354 <0.01 0.282 0.02 0.25 0.04 
N Stage 
(N2/3 vs N0/1) 
0.628 0.04 0.826 0.01 0.84 <0.01 
Overall Stage 
(3b vs 3a) 
0.259 0.09 0.200 0.20 0.21 0.17 
QIFs:       
Global 
Uniformity 
NI - NI - -6.11 0.02 
COM  
sum variance 
NI - NI - -0.0002 0.10 
Percent Air NI - NI - 1.26 0.53 
  Abbreviations: NI=not included in model; SCC=squamous cell carcinoma; GTV=gross tumor volume; KPS = Karnofsky 
performance status; SD= standard deviation; LA=largest axial slice 
The addition of GTV to the Cox model containing induction, KPS, N stage, and overall stage 
(i.e., the CPFs excluding GTV) led to a statistically significant improvement in model fit (p = 8 x 10-
6).  Adding the QIFs from Table 7 to the model using the CPFs including GTV also led to a statically 
significant improvement in model fit (p = 0.027).   
While comparisons of stratification on a Kaplan-Meier plot or c-indices are reasonable visual ways to 
assess for prognostic value, performing a likelihood ratio test on nested models is seen as the gold 
standard. Ultimately, it appears that QIFs from CE-CT add prognostic value but are not substantially 
adding information not accounted for from GTV or CPFs. Initially, it was somewhat surprising that 
the LOG_Average feature, which was significant in the Cohort 1 analysis, was not selected in this 
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analysis.  However, LOG_Average and COM sumvariance were significantly correlated (Pearson 
correlation coefficient = 0.91, p < 0.01). 
 
4.2 Results of Specific Aim 2: Analysis of FDG-PET-based Quantitative Image Features 
Specific Aim 2 examined PET-based quantitative image features for prognostic value, 
reproducibility, and volumetric stability.  
4.2.1 Results for Project 2.1: Quantify the impact of adding FDG-PET-based quantitative image 
features to outcome models containing only CPFs 
Twenty-eight QIFs were assessed in each fold of cross-validation. These features are shown 
in Table 9.   
Table 9. Extracted Quantitative Image Features for Cohort 3 (pretreatment FDG-PET) 
Intensity Histogram (IHIST)- Co-Occurrence Matrix (COM)+ Shape/Volume   
Mean* -- SUVmean 
Maximum* -- SUVmax 
Peak* -- SUVpeak 
Entropy 
Uniformity 
Standard Deviation 
Coefficient of Variation 
Cumulative Histogram 
Contrast 
Correlation 
Energy 
Homogeneity 
Volume* -- MTV 
Surface Area* 
Convex Hull Volume 
Solidity 
 
Presence of Necrosis 
 
*These features were calculated for the primary, nodal disease, and total disease (primary plus nodal) 
^ This features was only calculated for the nodal disease, and total disease (primary plus nodal) 
- Entropy, Uniformity, and cumulative histogram were generated using a bin size of 1 SUV. The other features used the raw 
SUV values 
+A bin size of 1 SUV was used for COM features. COM features were averaged across all 2D directions using all axial 
slices of the ROI.  
 
This table has been reused with the permission of the original publisher from the following publication:  Fried DV, Mawlawi O, Zhang L, 
Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative image features 
combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published online July 15, 2015. ©Radiological 
Society of North America. 
 
The predictive Kaplan-Meier curves generated from the cross-validated predictions of overall 
survival using CPFs excluding GTV, CPFs including GTV, and CPFs including GTV and QIFs are 
shown in Figure 23, Figure 24, and Figure 25, respectively. Local-regional control and freedom from 
distant metastases were assessed; however FDG-PET based QIFs did not appear to be prognostic for 
these outcomes. The p-values in the lower left of each figure represent the p-value of the associated 
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log-rank test.  The curves were divided into 5 risk groups via k-means clustering in order to 
demonstrate prediction calibration.  
 
 
 
Figure 23. Overall Survival Comparing Various Risk Groups (Defined Using K-Means 
Clustering from Low Risk to High Risk) Using Models Incorporating CPFs Excluding GTV.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Mawlawi O, Zhang L, 
Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative image features 
combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published online July 15, 2015. ©Radiological 
Society of North America. 
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Figure 24. Overall Survival Comparing Various Risk Groups (Defined Using K-Means 
Clustering from Low Risk to High Risk) Using Models Incorporating Cpfs Including GTV. 
 
 
Figure 25. Overall Survival Comparing Various Risk Groups (Defined Using K-Means 
Clustering from Low Risk to High Risk) Using Models Incorporating Cpfs Including GTV 
And QIFs.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Mawlawi O, Zhang L, 
Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative image features 
combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published online July 15, 2015. ©Radiological 
Society of North America. 
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Figure 26 illustrates the concordance indices for overall survival. 
 
Figure 26. Concordance Indices for Overall Survival in Cohort 3 (FDG-PET Based QIFs) 
Using Minimum Outcome Differences of 6, 12, 18, And 24 Months.  
This figure has been reused with the permission of the original publisher from the following publication:  Fried DV, Mawlawi O, Zhang L, 
Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative image features 
combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published online July 15, 2015. ©Radiological 
Society of North America. 
 
For overall survival predictions generated using CPFs including GTV and QIFs resulted in 
superior stratification of patients.  Furthermore, c-indices at every time point were greater for 
predictions generated using CPFs including GTV and QIFs (Figure 26). The inclusion of GTV to the 
other CPFs resulted in improved c-indices but the inclusion of QIFs always resulted in substantial 
further improvement.   
Table 10 illustrates the models developed from the cross-validation methodology using CPFs 
including GTV and QIFs. 
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Table 10. Overall Survival Models for Covariate Combinations in Cohort 3 
Covariates CPFs excluding GTV CPFs including GTV 
CPFs including  
GTV and QIFs 
CPFs: 
Coefficient p-value Coefficient p-value Coefficient 
p- 
value 
Age (continuous) 0.027 <0.01 0.029 <0.01 0.027 <0.01 
Induction -0.226 0.24 -0.130 0.52 -0.138 0.49 
T Stage 
(T1/2 vs T3/4) 
-0.200 0.25 -0.286 0.11 
-0.198 0.31 
Gender 
(Male vs Female) 
0.525 <0.01 0.506 0.01 
0.467 0.02 
GTV 
(Log2) 
NI - 0.196 0.02 
0.225 0.01 
KPS 
(<90 vs ≥90) 
0.257 0.07 0.202 0.16 
0.307 0.03 
Overall Stage 
(3b vs 3a) 
0.277 0.13 0.215 0.25 
NI - 
QIFs:       
COM Energy NI - NI - -7.23 0.05 
Solidity NI - NI - -0.780 <0.01 
Abbreviations: NI-not included in model, GTV-gross tumor volume, COM-co-occurrence matrix, CPFs – conventional 
prognostic factors 
This table has been reused with the permission of the original publisher from the following publication:  Fried DV, Mawlawi O, Zhang L, 
Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative image features 
combined with clinical prognostic factors. Radiology doi: 10.1148/radiol.2015142920. Published online July 15, 2015. ©Radiological 
Society of North America. 
The addition of GTV to the Cox model containing induction, KPS, T stage, gender and 
overall stage (i.e., the CPFs excluding GTV) led to a statistically significant improvement in model fit 
(p = 0.04).  Adding the QIFs from Table 9 to the model using the CPFs including GTV also led to a 
statically significant improvement in model fit (p = 0.007). Disease solidity (the volume of disease 
divided by the smallest convex volume that would be able to encompass all disease) along COM 
energy (a metric quantifying the uniformity of the SUV values within the primary) were the QIFs 
selected in all folds of cross-validation and were significantly (i.e., solidity; p < 0.01) or marginally 
significantly (i.e., COM energy; p = 0.05) associated with overall survival in the multivariate Cox 
model.   
The presence of necrosis and percent of tumor exhibiting necrosis were examined in a 
separate analysis. Neither of these features was selected in cross-validation nor were they significant 
using univariate or multivariate Cox proportional hazards analyses (p > 0.05).    
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While comparisons of stratification on a Kaplan-Meier plot or c-indices are reasonable visual 
ways to assess for prognostic value, performing a likelihood ratio test on nested models is seen as the 
gold standard. Ultimately, it appears that QIFs from CECT add prognostic value not accounted for by 
CPFs or GTV. 
4.2.2 Results for Project 2.2:  Quantify the reproducibility of FDG-PET-based quantitative image 
features using “pseudo” test-retest scans 
Cohort 6 was used to analyze the reproducibility of “pseudo” test-retest scans (i.e. patients 
having one scan taken at an outside institution followed by a scan taken at MD Anderson without any 
intervention between scans). The CCC was calculated for all 53 test-retest pairs, only pairs with 
different reconstruction dimensionality (2D vs 3D, n = 40), pairs with both scans having 3D 
reconstruction (n = 10), pairs with varying time differences between scans, pairs with <25% change 
in volume, and between scans acquired using different PET/CT models. The results from these 
analyses are shown in Table 11. Representative features were chosen from the various QIF types as 
shown in Table 9.  Of note, the average CCC is more reasonable than expected at 0.78 using all 
scanners and imaging parameters. Furthermore, it can be seen that the QIF reproducibility improves 
when both scans are obtained using 3D reconstruction techniques versus a mix of 2D and 3D 
reconstruction (average CCC = 0.93 vs 0.72). Reproducibility also apparently worsens when scans are 
separated in time by more than 61 days (average CCC = 0.81 vs 0.62). Based on this data, 
standardization of PET acquisitions could lead to more reproducible QIFs and potentially enhance 
prediction models.    
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Table 11. CCC Values from “Pseudo” Test-Retest PET Scans 
 
All Reconstruction Type 
Time Difference  
(days) 
Low  
Volume 
Change 
Model Type 
QIF 
All 
(N = 53) 
2D - 3D 
(n = 40) 
3D - 3D 
(n = 10) 
0-30 
(n = 16) 
31-60 
(n = 25) 
61+ 
(n = 12) 
<25%  
(n=24) 
ST-RX 
(n = 15) 
ST-STE  
(n=11) 
Volume 0.92 0.92 0.97 0.93 0.86 0.95 0.99 0.96 0.92 
Surface Area 0.93 0.93 0.97 0.94 0.87 0.96 0.99 0.97 0.93 
Entropy 0.82 0.8 0.95 0.79 0.87 0.62 0.84 0.88 0.75 
Max 0.84 0.76 0.95 0.82 0.89 0.67 0.8 0.87 0.86 
Peak 0.78 0.72 0.9 0.8 0.81 0.36 0.78 0.85 0.81 
Mean 0.85 0.78 0.96 0.82 0.87 0.81 0.86 0.87 0.91 
Std 0.87 0.8 0.96 0.83 0.93 0.68 0.85 0.89 0.92 
Uniformity 0.77 0.78 0.9 0.72 0.82 0.52 0.74 0.84 0.54 
Kurtosis 0.66 0.37 0.09 0.87 0.42 -0.11 0.4 0.47 0.28 
Skewness 0.57 0.54 0.26 0.76 0.46 0.35 0.58 0.47 0.43 
COMContrast 0.93 0.62 0.97 0.88 0.98 0.5 0.64 0.87 0.95 
COMCorrelation 0.77 0.7 0.93 0.71 0.82 0.74 0.69 0.88 0.5 
COMEnergy 0.6 0.67 0.54 0.63 0.56 0.32 0.55 0.68 0.31 
COMHomogneity 0.7 0.69 0.87 0.53 0.79 0.61 0.66 0.8 0.68 
cumHistogram 0.71 0.62 0.8 0.81 0.64 0.71 0.7 0.78 0.63 
          
Average 
 (all metrics) 
0.78 0.72 0.93 0.81 0.82 0.62 0.74 0.87 0.75 
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4.2.3 Results for Project 2.3: Quantify the reproducibility of FDG-PET-based quantitative image 
features using retrospective reconstructions of phantom and patient data 
The percent of voxels less than 1 or 2 SUV using the NEMA IEC phantom, as described in 
Section 3.6, is shown below in Table 12. 
Table 12. Percent of Sphere Voxels with a Maximum Change in SUV <1 or < 2 
Scanner Matrix Size %Voxels < 1 SUV %Voxels < 2 SUV 
VCT 
128 92 99 
256 75 94 
710 
128 80 98 
192 61 88 
256 62 90 
mCT 
128 91 98 
200 72 90 
256 69 88 
 
QIF values were extracted from each of the three scanners using the various reconstruction 
parameters using fixed contours of the spheres. The median, mean, and standard deviation seen within 
each scanner and across all scanners were calculated and compared to the values from the patient data in 
terms of their standard deviations (Table 13).  In addition, the same process was performed using 6 
lesions from 5 different patients. The ratio of Cohort 3 patient standard deviation for each feature to the 
standard deviation observed in the 6 test lesions are shown in Table 14.  
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Table 13. Change in QIF Values due to Variation in Reconstruction Parameters and Comparison 
to Variation in Cohort 3 Patient QIF Values 
Scanner Metric Contrast Correlation Energy  Homogeneity Uniformity SUVmax SUVmean SD Entropy 
All min 2.53 0.21 0.014 0.35 0.103 10.3 5.0 2.9 2.88 
All max 25.91 0.86 0.044 0.59 0.169 17.2 6.9 4.3 3.50 
All median 12.15 0.58 0.023 0.44 0.119 12.8 5.9 3.6 3.27 
All mean 12.91 0.54 0.024 0.44 0.123 13.1 5.9 3.6 3.27 
All SD 6.76 0.21 0.008 0.07 0.015 1.8 0.5 0.3 0.16 
VCT min 2.53 0.40 0.023 0.41 0.122 10.3 5.0 2.9 2.88 
VCT max 15.57 0.86 0.044 0.59 0.169 12.4 5.2 3.5 3.27 
VCT median 7.86 0.62 0.03 0.47 0.13 11.2 5.1 3.3 3.16 
VCT mean 8.61 0.63 0.03 0.49 0.137 11.1 5.1 3.3 3.11 
VCT SD 5.31 0.21 0.007 0.07 0.015 0.7 0.1 0.2 0.12 
710 min 4.90 0.21 0.015 0.36 0.103 11.3 6.0 3.2 3.09 
710 max 25.91 0.78 0.041 0.52 0.14 17.2 6.9 4.3 3.50 
710 median 12.15 0.58 0.026 0.46 0.117 14.7 6.5 3.9 3.35 
710 mean 14.52 0.51 0.026 0.44 0.119 14.2 6.4 3.8 3.31 
710 SD 7.19 0.21 0.009 0.06 0.013 1.6 0.3 0.3 0.15 
mCT min 5.04 0.21 0.014 0.35 0.104 11.1 5.7 3.4 3.10 
mCT max 24.33 0.77 0.033 0.51 0.136 15.9 6.1 4.1 3.48 
mCT median 13.55 0.56 0.017 0.41 0.114 13.1 5.9 3.7 3.36 
mCT mean 14.26 0.51 0.019 0.42 0.117 13.2 5.9 3.7 3.33 
mCT SD 6.25 0.20 0.005 0.05 0.01 1.4 0.1 0.2 0.12 
           
Cohort 3 
Patients 
SD 17.1 0.17 0.031 0.11 0.07 7.5 3.7 1.7 0.68 
           
All 
SDpts/
SDphan 
2.53 0.83 3.69 1.66 4.43 4.22 6.77 4.81 4.33 
VCT 
SDpts/
SDphan 
3.22 0.84 4.31 1.50 4.27 10.64 63.92 8.11 5.72 
710 
SDpts/
SDphan 
2.38 0.83 3.52 1.90 5.19 4.82 11.66 5.19 4.50 
mCT 
SDpts/
SDphan 
2.74 0.85 5.90 2.02 6.87 5.41 29.08 6.87 5.85 
SD = standard deviation; SDpts = Cohort 3 patient standard deviation; SDphan; phantom standard deviation; 
SDpts/SDphan = ratio of standard deviation between Cohort 3 patient and phantom values; min = minimum value 
observed for the particular feature for the scanner used across the different parameters (18 total images); max = 
maximum value observed for the particular feature for the scanner used across the different parameters (18 total 
images); median = median value observed for the particular feature for the scanner used across the different 
parameters (18 total images); mean = mean value observed for the particular feature for the scanner used across the 
different parameters (18 total images); SD = standard deviation of values observed for the particular feature for the 
scanner used across the different parameters (18 total images) 
 
 
 
 
 
 
 
 
 
81 
 
Table 14. Change in QIF Values from Patient Scans due to Variation in Reconstruction 
Parameters and Comparison to Variation in Patient QIF Values 
 
Contrast Correlation Energy Homogeneity Uniformity SUVmax SUVmean SD Entropy 
Patient Ratio 1 7.82 1.42 5.11 1.85 15.03 10.05 20.45 10.44 10.05 
Patient Ratio 2 9.45 1.26 8.81 2.36 10.49 12.72 13.89 13.37 9.92 
Patient Ratio 3 3.24 0.94 11.54 1.83 11.11 6.89 22.48 5.62 7.68 
Patient Ratio 4a 9.30 1.43 5.68 2.19 6.78 4.36 26.90 7.27 6.32 
Patient Ratio 4b 3.71 1.61 13.37 2.50 16.62 3.69 22.34 5.02 8.14 
Patient Ratio 5 2.71 1.35 21.97 2.48 15.57 4.93 25.52 5.30 6.97 
          
Average Patient Ratio 6.04 1.33 11.08 2.20 12.60 7.11 21.93 7.84 8.18 
Phantom Ratio - 710 2.38 0.83 3.52 1.90 5.19 4.82 11.66 5.19 4.50 
 
4.3 Results of Specific Aim 3: Assess relationships between CT-based quantitative image features, PET-
based quantitative image features, conventional features, and morphologic features 
Specific aim 3 examined whether relationships exist between CT-based quantitative image 
features, PET-based quantitative image features, conventional features, and morphologic features. 
Correlations were investigated using features identified in previous analyses, such as COM energy and 
solidity in PET and LOG_Average and Uniformity in CE-CT. Uniformity in PET was also tested as it 
was found to be strongly correlated with COM energy and is calculated in the same fashion only without 
taking into account 2D displacement associations.   
 
4.3.1 Results for Project 3.1: Quantify correlations between prognostic FDG-PET-based and CECT-
based quantitative image features 
Cohort 4 was used for determining correlations between PET and CE-CT QIFs that were found to 
have prognostic value in sections 4.1.1 and 4.2.1. FDG-PET based uniformity was also added to this list 
as it was found to be significantly correlated to COM Energy and have a very similar formula for 
quantification. Table 15 shows the Pearson correlation coefficients and associated p-values testing 
whether two metrics are significantly correlated. 
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Table 15. Correlations between PET and CE-CT Features  
 CE-CT QIFs 
FDG-PET QIFs LOG_Average Uniformity 
COM Energy -0.32 (p = 0.005) -0.005 (p = 0.96) 
Solidity 0.31 (p = 0.006) 0.26 (p = 0.02) 
Uniformity -0.41 (p = 0.0002) -0.03 (p = 0.80) 
 
The LOG_Average from CE-CT was associated with the 3 examined PET QIFs. Uniformity from 
CE-CT was significantly correlated with solidity but not with COM energy or uniformity. This data found 
that patients having heterogeneous FDG-uptake in the primary tumor and more dispersion between 
primary and nodal disease were correlated with tumors found to have high intensity and/or frequent edges 
on CE-CT. While statistically significant in many cases, the correlation coefficients were quite low across 
all comparisons. Graphical representations plotting CE-CT QIFs versus FDG-PET QIFs are shown in 
Figure 27.  This implies that relationships do exist between QIFs from different modalities; however they 
by no means can be used interchangeably. For example, in Figure 27 it is clear that in the bottom left 
figure comparing CE-CT LOG_Average to FDG-PET uniformity that higher values of FDG-PET 
uniformity are associated with lower values of CE-CT LOG_Average. However, one could not simply use 
CE-CT LOG_Average and accurately determine the FDG-PET uniformity. For instance, having an FDG-
PET uniformity value of 0.1 is associated with CE-CT LOG_Average values ranging from 1 to 4.5.  
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Figure 27. Assessment of Correlations between Prognostic CE-CT QIFs (LOG_Average and 
Uniformity) and Prognostic FDG-PET QIFs (COM Energy, Solidity, and Uniformity) 
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4.3.2 Results for Project 3.2: Quantify if relationships exist between CE-CT-based and FDG-PET-based 
quantitative image features with tumor volume and TNM staging 
Cohort 2 was used to determine if relationships existed between CE-CT QIFs and tumor volume 
(volume = primary volume and GTV = primary volume + nodal volume) or TNM staging.  Cohort 3 was 
used to determine if relationships existed between FDG-PET QIFs and tumor volume or TNM staging. 
When comparing to FDG-PET QIFs, both the primary and GTV (i.e., the metabolic tumor volume, MTV) 
were determined from the contours on the FDG-PET scan and not based on the CT. Box plots relating 
CE-CT and FDG-PET QIFs are shown below in 
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Figure 28 and Figure 29, respectively. The p-values were determined from Wilcoxon rank-sum 
tests.    
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Figure 28. Comparison of LOG_Average and Uniformity from CE-CT Versus Tumor Volume 
and Staging 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
Figure 29. Comparison of COM Energy, Uniformity, and Solidity from FDG-PET versus Tumor 
Volume and Staging  
 
Significant differences in CE-CT, LOG_Average, and CE-CT uniformity were observed between 
various CPFs. Significant differences in FDG-PET COM energy, solidity and uniformity were also 
observed between various CPFs. Uniformity was significantly different when stratified by primary tumor 
volume, GTV, and T stage.  FDG-PET based COM energy was significantly different when stratified by 
primary volume, T stage, and N stage. FDG-PET based solidity significantly differed when stratified by 
all tested CPFs. FDG-based uniformity was significantly different when stratified by primary tumor 
volume, GTV, and T stage. Significant differences were observed between QIFs when stratified by CPFs. 
The results of Specific Aims 1 and 2 suggest that even though relationships exist between QIFs and CPFs, 
QIFs provide additional prognostic information. 
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4.3.3 Results for Project 3.3: Quantify if there are correlations between FDG-PET-based quantitative 
image features, CECT-based quantitative image features, and morphologic characteristics (vessels, 
necrosis, air cavities, etc.) 
Radiologists routinely observe morphologic characteristics of tumors such as the presence of 
necrosis, cavitation, and heterogeneous enhancement when examining CE-CT images. The purpose of 
this project was to quantitatively assess how morphologic features influence the prognostic QIFs found in 
sections 4.1.1 and 4.2.1. Sections 3.3.5 Contrast Enhanced CT Auto-segmentation of Morphologic 
Characteristics and 3.3.6 PET Necrosis Auto-segmentation describe how morphologic characteristics can 
be extracted in a quantitative fashion.  Namely, these sections describe the extraction and quantification 
of volume and percent of the tumor that consists of vessels, necrosis, air cavities, and tumor tissue. 
Features quantifying vessels, necrosis, air cavities, and tumor tissue are able to be extracted from CE-CT 
and features regarding necrosis are able to be extracted from PET.  Figure 30 displays boxplots of 
dichotomous comparisons between QIFs and the presence/absence of tissue types and their associated p-
values as determined by the Wilcoxon rank-sum test. 
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Figure 30. Comparison of LOG_Average and Uniformity on CE-CT versus The 
Presence/Absence of Various Tissue Types 
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Figure 31 and Figure 32 below compare the extracted necrosis volume and necrosis percentage of 
tumor from FDG-PET and CE-CT auto-segmentations, respectively.    
 
Figure 31. Comparison of Necrosis Volumes Determined By FDG-PET Vs CE-CT 
 
Figure 32. Comparison of Necrosis Percentage Determined By FDG-PET vs CE-CT 
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The CCC values from Figure 31 and Figure 32 were 0.85 and 0.76, respectively. It was observed 
that the auto-segmentation from CE-CT identified more small regions of necrosis compared to the auto-
segmentation from FDG-PET.  In general, the agreement seen between the two methodologies was 
reasonable based on their CCC values.  
In addition to quantifying correlations between PET, CE-CT, and morphologic characteristics, it 
was important to determine how the presence of morphologic characteristics influences QIF metrics. To 
investigate this, plots were generated (Figure 33) comparing the original (i.e., total tumor) to the original 
tumor ROI excluding certain tissue types. The details of these analyses are described in 3.3.5 Contrast 
Enhanced CT Auto-segmentation of Morphologic Characteristics. 
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Figure 33. Comparison of CE-CT Feature Value for Entire Tumor (X-Axis) with Feature Value 
Excluding a Particular Tissue Type or Types (Only Tissue: Excludes Air, Necrosis, and Vessels). 
(A) Comparison of LOG_Average Values from Tumors with Enhancing Vessels when the 
Vessels Are Present (X-Axis) or Excluded (Y-Axis). (B) Comparison of Uniformity Values from 
Tumors with Enhancing Vessels when the Vessels are Present (X-Axis) or Excluded (Y-Axis). 
(C) Comparison of LOG_Average Values from Tumors with Necrosis when the Necrosis Is 
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Present (X-Axis) or Excluded (Y-Axis). (D) Comparison of Uniformity Values from Tumors 
with Necrosis when the Necrosis Is Present (X-Axis) or Excluded (Y-Axis). (E) Comparison of 
LOG_Average Values from Tumors with Cavitation when the Cavitation Is Present (X-Axis) or 
Excluded (Y-Axis). (F) Comparison of Uniformity Values from Tumors With Cavitation when 
the Cavitation Is Present (X-Axis) or Excluded (Y-Axis). 
 
All R2 values from the plots in Figure 33 were greater than 0.81. Excluding enhancing vessels 
and/or necrotic regions led to a decrease in measured LOG_Average values and an increase in uniformity 
values. As expected, a decrease in LOG_Average (metric quantifying number and intensity of “edges” 
within the tumor) led to an increase in uniformity. Figure 33E and Figure 33F illustrate that analyzing 
only tumor tissue (i.e., excluding necrosis and enhancing vessels) yielded different values of 
LOG_Average and intensity histogram uniformity when compared to the total tumor including all 
morphologic tissue types (p = 0.001 and  = 0.037, respectively).  While these values are statistically 
different, the R2 values are generally very high (greater than 0.81). This implies that while statistically 
different, the values are still highly related. No differences were found when comparing uniformity values 
between tumors with above or below average volumes of vessels or necrosis based on our sampled 
cohort. However, it was found that tumors with above average volume of vessels and necrosis were found 
to have significantly higher values of LOG_Average (p < 0.01) for both the total tumor contour and ROI 
excluding these morphologic features.  
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4.4 Results of Specific Aim 4: Potential use of FDG-PET-based quantitative image features 
4.4.1 Results for Project 4.1: Assess whether significant PET-based quantitative image features relate to 
a difference in patient survival for those treated with an escalated radiation dose   
Section 4.2.1 was able to identify FDG-PET based QIFs that appeared to be prognostic for patient 
survival. The purpose of this project was to see if these QIFs could be used to identify patients that would 
benefit from receiving an escalated radiation dose. We hypothesized that patients with primary tumors 
with uniform FDG-uptake (i.e. high values of COM energy) may benefit from dose escalation as 
heterogeneous FDG-uptake has been associated with poor pathologic factors, aggression, and inferior 
outcome. Additionally, we also hypothesized that patients with non-dispersed local-regional disease (i.e. 
high values of solidity) could also potentially benefit from dose escalation as these patients are probably 
less likely to develop metastatic disease and would result in less dose delivered to cardiothoracic normal 
tissue structures (this was confirmed in an analysis shown in Appendix D: Relationship of Cardiothoracic 
Dosimetry with Disease Solidity). The development of metastatic disease would reduce the survival 
impact associated with an increase in local control and higher normal tissue doses have been shown to 
reduce patient survival. Therefore, we chose to investigate the impact of dose escalation considering both 
patient COM energy and disease solidity. Since high values of each feature were hypothesized to be 
beneficial with increased radiation dose, we assessed the impact of creating sub-cohorts of patient with 
high values of both COM energy and disease solidity.   
We first stratified all patients in Cohort 3 by radiation dose (74 Gy vs 60-70 Gy). Dose escalation 
did not result in a difference in overall survival or progression-free survival (Figure 34).   
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Figure 34. Stratification of Overall Survival and Progression-Free Survival by Dose Level in All 
Patients within Cohort 3 
 
A grid search was performed to examine different combinations of sub-cohorts as determined by 
varying cutoffs of the QIFs found to be prognostic in 4.2.1 Results for Project 2.1 (i.e., solidity and COM 
energy). Initially, the search was performed to isolate patients with homogeneous SUVs within the 
primary tumor (high COM energy) and close proximity of disease (high solidity). The results of this 
search are seen in Figure 35. The values within the figures are the p-values from a log-rank test when 
stratifying the specific sub-cohort by dose level. Values at the top left have mild cutoffs in terms of the 
QIFs and thus include majority of all patients (180/195). Values progressively closer to the bottom right 
have more strict cutoffs in terms of QIFs and include patients with progressively higher values. As higher 
and higher cutoffs are implemented for the QIFs, the p-values from the log-rank test between dose levels 
become significant for both overall survival and progression-free survival.  
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Figure 35. Log-Rank P-Values from Sub-Cohorts Based on High Values FDG-PET QIFs In 
Terms Of Overall Survival (A) and Progression-Free Survival (B) 
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Kaplan-Meier plots from the sub-cohort in the cell with the dashed white outline Figure 35 are 
shown in Figure 36.  In this sub-cohort, patients receiving an escalated dose of 74 Gy had superior overall 
survival and progression-free survival compared to those receiving 60-70 Gy (p = 0.01 and 0.02, 
respectively).   
 
Figure 36. Kaplan-Meier Plots Stratified by Dose Level for The Sub-Cohort with High Values 
Of FDG-PET QIFs In Terms of Overall Survival and Progression-Free Survival 
 
The opposite association (i.e., impact of low values of COM energy and solidity) was examined 
in the same manner. The results of this search are seen in Figure 37. Values at the bottom right now have 
mild cutoffs in terms of the QIFs and thus include the majority of all patients (179/195). Values 
progressively closer to the top left have more strict cutoffs in terms of QIFs and include patients with 
progressively lower values. It can be seen as more strict cutoffs are implemented for the QIFs, the p-
values from the log-rank test between dose levels become significant for both overall survival and 
progression-free survival. 
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Figure 37. Log-Rank P-Values from Sub-Cohorts Based on High Values of FDG-PET QIFs In 
Terms of Overall Survival(A) and Progression-Free Survival(B) 
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Figure 38. Kaplan-Meier Plots Stratified by Dose Level for the Sub-Cohort with Low Values of 
FDG-PET QIFs In Terms of Overall Survival and Progression Free Survival 
 
Kaplan-Meier plots from the sub-cohorts in the cells with the dashed white outlines in Figure 37 
are shown in Figure 38.  In this sub-cohort, patients receiving an escalated dose of 74 Gy had inferior 
overall survival and progression-free survival compared to those receiving 60-70 Gy (p = 0.02 and 0.025, 
respectively).   
Furthermore, using a multivariate Cox model, receiving 74 Gy versus 60-70 Gy was an 
independent prognostic factor for both overall survival (high value QIFs: p = 0.012, low value QIFs: p = 
0.02) and progression-free survival (high value QIFs: p = 0.015, low value QIFs: p = 0.025) when 
adjusting for overall stage, T stage, receiving induction chemotherapy, age, gender, and GTV.  These 
CPFs were used as they were selected during cross-validation in our previous work in 4.2.1 Results for 
Project 2.1: Quantify the impact of adding FDG-PET-based quantitative image features to outcome 
models containing only CPFs. 
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Table 16. Comparison of Conventional Prognostic Factors  
  High QIFs Values Subgroup   
Low QIFs Values  
Subgroup 
  74Gy 60-70Gy p-value   74Gy 60-70Gy p-value 
Mean GTV (cc) 200 219 0.69   192 186 0.87 
Age (mean) 65 63 0.49   67 63 0.18 
MTV (cc) 118 123 0.91   104 126 0.44 
Overall Stage     0.31       0.79 
3a 24 28     16 25   
3b 7 15     8 16   
KPS     0.3       0.78 
60 0 3     1 3   
70 3 2     1 3   
80 18 29     16 20   
90 10 8     6 14   
100 0 1     0 1   
Induction     0.29       0.42 
No 21 34     18 26   
Yes 10 9     6 15   
Concurrent     0.51       0.38 
No 0 2     0 3   
Yes 31 41     24 38   
Adjuvant     1       0.25 
No 20 27     20 28   
Yes 11 16     4 13   
Histology     0.24       1 
Squamous Cell 11 22     10 16   
Other 20 21     14 25   
Smoking     0.1       0.44 
Never 0 4     1 4   
Former 23 23     19 26   
Current 8 16     4 11   
Gender     0.03       1 
Male 27 27     9 16   
Female 4 16     15 25   
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Figure 34 though Figure 38 demonstrate that the QIFs found to be prognostic in section 4.2.1 
Results for Project 2.1: Quantify the impact of adding FDG-PET-based quantitative image features to 
outcome models containing only CPFs were capable of identifying sub-cohorts of patients whose survival 
was influenced by dose escalation. Dose escalation did not appear to influence patient survival on the 
entire cohort. Figure 35 and Figure 37 show that these observations followed a definite trend and were not 
purely the result of selecting a significant result from a large number of tests. Dose escalation was found 
to be prognostic in the isolated sub-cohorts even when controlling for CPFs such as overall stage, T stage, 
receiving induction chemotherapy, age, gender, and GTV. The lack of imbalances in Table 16 implies 
that CPFs do not appear to be responsible for the observed survival differences.   
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Chapter 5 Discussion 
Discussion Specific Aim 1 
We hypothesized that the addition of CT-based quantitative image features would significantly 
improve outcome models compared to models using conventional prognostic factors.  This hypothesis 
was confirmed as the addition of CT-based quantitative image features significantly improved outcome 
models compared to models using conventional prognostic factors. QIFs extracted from CT were able to 
improve model fit compared to models using CPFs excluding or including GTV. The initial analysis of 
Cohort 1 (91 patients with a pretreatment TAVG, T50, and CE-CT) found that the addition of QIFs improved 
the stratification of patient outcome compared to models using CPFs including or excluding GTV.  In 
addition, incorporating the reproducibility of QIFs yielded a percent classification reproducibility of 
approximately 80%. QIFs from CE-CT were found to be the most significant in terms of prognostic value 
for patient outcome between CT types but were far less reproducible compared to features from TAVG and 
T50.  The choice to analyze only CE-CT images in Cohort 2 was based on data from Cohort 1 that found 
the most significant source of prognostic information was from the features extracted from CE-CT.  
Having contrast injected facilitates greater HU differences within the tumor due to the contrast infiltrating 
vessels and subsequently into the tissue. We hypothesized this may be the reason the CE-CT derived 
features were more prognostic than those from the non-contrast 4D-CT. Therefore, we decided to develop 
a cohort of patients who only needed to have a CE-CT regardless of whether they received a 4D-CT scan.  
The analysis of Cohort 2 (249 patients with a pretreatment CE-CT) found that QIFs significantly 
improved model fit but did not improve the c-indices or patient stratification. These results suggest that 
CE-CT-based QIFs are associated with a statistically significant improvement in outcome model fit using 
the most sensitive test (log-likelihood ratio).  However, the results would probably not be considered a 
clinically significant improvement in predictive ability since neither the c-index nor visual stratification 
appeared to improve. 
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The results suggest that CT QIFs and more specifically CE-CT-based QIFs may be useful in 
patient outcome modeling. CT-based QIFs have the potential to develop clinically useful prediction 
models using medical images that are already obtained during routine patient staging. Therefore, 
implementation would require little to no added cost and would not require additional time, discomfort, or 
radiation dose to patients.  The ability to stratify patients in ways shown to be superior to current staging 
methods might allow physicians to deliver more optimized, patient-specific treatment.  While our initial 
analysis of Cohort 1 appeared more efficacious in terms of LRC and FFDM, ultimately stratifying 
patients in terms of overall survival would generate the most benefit to physicians and patients alike. Our 
analysis of Cohort 2 using only CE-CT scans did result in improved c-indices and stratification but these 
results may be due to the elevated prognostic ability of CPFs including GTV. The impact of CPFs and 
GTV seen in Cohort 2 is far superior to what was seen Cohort 1 (91 pts), Cohort 3 (195 pts), and Cohort 4 
(77 pts). Since QIFs from CE-CT were still significant in improving model fit in Cohort 2, it is possible 
that improved stratification may be possible in alternative cohorts even though this was not observed in 
our analysis. There is a relatively extensive body of literature supporting the idea that QIFs are prognostic 
in NSCLC with a vast majority performed using non-contrasted CT scans.10, 14, 15, 48–50 However, work by 
Ravanelli et al. did find that CE-CT based QIFs (tumor uniformity * grey level) was able to predict 
response to first-line chemotherapy in NSCLC.51 Additionally, Al-Kadi and Watson also found that 
fractal based QIFs from CE-CT were able to predict  malignant aggressiveness in NSCLC.16 Aerts et al. 
(in non-contrast CT) did find evidence that QIFs improved NSCLC patient outcome stratification in 
addition to tumor volume and staging.  
Project 1.2 found that a majority of QIFs from CE-CT did not have a CCC value greater than 0.9. 
This could be due to the fact that these were not performed in a traditional test/retest fashion but were 
scans taken at different institutions separated by an average of 38 days. Differences in imaging within the 
ten patients, such as scanner type, manufacturer, imaging parameters, contrast timing, etc. (see 17), along 
with growth/underlying change in the tumor could easily be responsible for the low feature 
reproducibility. 
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Table 17. CE-CT Test/Retest Scan Information 
Field Outside Scan (n = 10) MD Anderson Scan (n = 10) 
Pixel Dimension (range) 0.70 – 0.86 0.78 – 0.86 
Manufacturer/Model   
GE/Lightspeed 16 0 7 
GE/Lightspeed VCT 2 2 
GE/Lightspeed Plus 1 1 
GE/Lightspeed Ultra 2 0 
GE/Lightspeed Pro 1 0 
Phillips/Brilliance64 1 0 
Toshiba/Aquilon 2 0 
Siemens/Sensation 16 1 0 
Reconstruction Kernel   
Standard 8 10 
FC03 1 0 
FC13 1 0 
 
 The definition of a CCC value of 0.9 being “reproducible” is also somewhat arbitrary.  While 
this value may be justified for assessing reproducibility of some measurements (e.g., measuring the 
dimensions of an object), this cut-off value may not be ideal in our context. Models including covariates 
with a CCC lower than 0.9 could feasibly still generate valuable information and be independently 
validated. For example, a patient’s performance status has been shown to be vital in predicting survival. 
Yet, assigning performance status is quite subjective between physicians and may not be reproducible in 
the sense of quantitatively having a CCC index greater than 0.9.  The summary of the results for Specific 
Aim 1 projects (1.1-1.3) are shown in Table 18. 
 
 
 
 
 
 
 
106 
 
Table 18. Summary of Results for Specific Aim 1 Projects 
Hypothesis Result(s) 
Project 1.1 Quantify the impact of 
adding CT-based quantitative image 
features to outcome models containing 
only CPFs including and excluding 
GTV 
OS stratification: p=0.046 
LRC stratification: p=0.01 
FFDM stratification: p=0.005 
Project 1.2 Quantify the 
reproducibility of CT-based 
quantitative image features and its 
impact on outcome models 
% QIFs where CCC > 0.9 
Tavg (85%) 
T50 (75%) 
CE-CT(23%) 
 
Reproducibility: 78-80% 
Project 1.3 Quantify the prognostic 
value of adding CE-CT-based 
quantitative image features to outcome 
models containing only CPFs 
Likelihood Ratio Test: 
p = 0.027 
 Stratification not improved 
 
While the addition of CT-based QIFs into survival models has shown significant potential, 
various downsides do exist.  Data is still only available from preliminary studies, which require external 
validation and appropriate assessment of predictive power/accuracy.  Careful consideration, of values for 
parameters involved with each methodology as well as whatever preprocessing steps are applied, needs be 
taken in deciding which QIFs/analysis methods are appropriate for particular tasks. Differing 
quantification methods and their associated parameters have the potential to greatly impact study results.  
Quantitative analysis is also not applicable to all patients.  Those with a small primary tumor or severe 
imaging artifacts are not appropriate to undergo analysis.  Advances in robust, auto-segmentation 
methods would also be exceedingly useful in this field in order to standardize tumor contouring.  
Physician-generated contours are most commonly used in these types of analyses but are far from perfect.  
Thresholding is a useful strategy to enhance contour reproducibility, particularly in lung tumors.  Other 
factors that would influence reproducibility but not included in our analysis are the stability of the CPFs 
between institutions/physicians, such as staging, performance status, tumor volume, etc. Additionally, in 
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this study the imaging protocols were well controlled.  The impact of changing image parameters (e.g., 
tube voltage, reconstruction algorithm, pixel size, manufacturer, etc.) as well as consistency of QIFs 
should be considered when evaluating data from multiple institutions. Multiple groups have investigated 
the impact of variation in imaging on feature reproducibility.41, 48, 52 Balagurunathan et al. found that only 
30% of features examined were reproducible using test/retest scans with a criteria of having a CCC 
greater than or equal to 0.9 and approximately one third of these features were redundant.52 Hunter et al. 
identified that QIFs are not only dependent on the scanner type but also image phase on 4D-CT.41 Care 
should always be taken when determining the appropriateness of feature calculations used for each 
application.  
Our work builds upon the preliminary evidence shown in recent publications supporting the use 
of CT-based QIFs in NSCLC.10, 14, 15, 48–50 Our chosen patients are different in that our cohorts are 
comprised only of patients deemed stage III rather than multiple stages. Furthermore, we examined QIFs 
in relation to a more substantial list of CPFs whereas most of the literature does not perform multivariate 
comparisons or adjust for one or two CPFs such as volume and/or staging. Our analysis of cohort 1 found 
that the LOG_Average feature was significant across multiple outcomes. This supports the findings of 
Ganeshan et al. that have multiple reports of this feature type being significant not only in NSCLC but in 
other disease sites such as liver, breast, and esophageal cancers.10, 14, 15, 17, 19, 27, 28 Our analysis of cohort 2 
found that histogram uniformity was significant in multivariate analysis relating to patient survival. Aerts 
et al. used this feature (called total energy in their work [not to be confused with our COM energy 
feature]) as part of a radiomics signature that was found to be prognostic in both NSCLC and head and 
neck cancer cohorts in addition to relating to tumor gene-expression.8 Furthermore, their energy feature 
alone (i.e. not in a radiomics signature) was able to stratify patient survival in both NSCLC and head and 
neck cancer cohorts and these results were independently validated. However, this work was done using 
non-contrasted CT scans.  
Large, prospective studies are required in order to fully understand the potential impact that CT-
based QIFs could have on outcome prediction models. This work represents a good foundation from 
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which prospective studies could be based on due to the use of cross-validation and preliminary analysis of 
reproducibility. Further work needs to investigate QIFs’ role as a potential source of prognostic 
information as well as ways to ensure/correct for variation in features due to differences in scanners, 
reconstruction, phase (in 4D-CT), etc. Taking into account feature robustness alongside prognostic 
potential is necessary. Data needs to be collected to assess whether images and/or QIFs can be 
“normalized” and/or “corrected” to a particular baseline in terms of scanner, reconstruction, etc. to 
facilitate large scale investigations. Issues relating to the use of contrast material also need additional 
exploration. Very little is known regarding the impact of injection timing or the use of contrast versus 
non-contrasted scans. A cohort of NSCLC patients receiving sequential CT scans in the area of their 
primary tumor after contract injection would be valuable in determining the impact of scan timing post 
injection on QIFs. Furthermore, a cohort of patients receiving both non-contrasted and CE-CT and 
comparing the resulting QIFs should be performed to assess the impact of contrast on feature values.  
Our work provides some insight as to the influence of contrasted vessels on prognostic CT-based 
QIFs, but additional work validating our findings/methods increase our understanding of what these 
features may or may not be ultimately measuring. In general, more uniformity across all aspects of feature 
analysis (such as homogenizing features extracted, feature nomenclature, feature formulas, feature 
parameters used, modeling techniques, image acquisition, etc.) needs to be implemented for the field to 
advance. This process of homogenizing workflow should be the focus of future research in order to 
properly vet the ability of QIFs to provide prognostic information in addition to what is already known 
from CPFs.   
Discussion Specific Aim 2 
We hypothesized that the addition of FDG-PET-based quantitative image features will 
significantly improve outcome models compared to models using conventional prognostic factors. This 
hypothesis was confirmed as the addition of FDG-PET-based quantitative image features significantly 
improved outcome models compared to models using conventional prognostic factors. Incorporating 
pretreatment PET QIFs alongside CPFs in survival models enabled improved model fit and better 
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stratification of patients in terms of overall survival compared to models using CPFs alone.  The use of 
cross-validation allows the use of all data in both training and testing and thus is more efficient than 
splitting data into independent test and validation sets. The results from cross-validation should more 
aptly reflect how the model would perform in an independent cohort comprised of similar patients. 
 Recent data has suggested that quantification of intratumoral heterogeneity may yield prognostic 
information that could improve prediction or response and/or prognosis in patients with NSCLC.12, 21, 23  It 
is hypothesized that tumor heterogeneity in FDG-PET tracer uptake may reflect underlying tumor biology 
such as hypoxia, angiogenesis, and necrosis.14 Therefore, these methods could be used to identify tumors 
that are predisposed to aggressive behavior.  In NSCLC specifically, preliminary data suggests a 
relationship between QIFs and patient outcome.12, 21  However, these studies do not sufficiently adjust for 
CPFs when assessing significance of new QIFs.  This work is unique in that significant effort was made 
to generate multivariate models that implement both QIFs and CPFs to assess the added benefit of QIFs to 
models using CPFs. Furthermore, prediction models frequently utilize cohorts comprised of patients of 
varying stages whereas our cohort is comprised solely of stage III NSCLC.  Models capable of stratifying 
patients that are homogeneously staged may be more clinically useful as different stages of disease 
frequently dictate different treatment courses.  Furthermore, solidity and COM energy were consistently 
selected during cross-validation and conventional PET metrics, such as SUVmean, SUVmax, MTV, etc. , 
were not selected with nearly the same frequency.  This observation suggests that perhaps QIFs 
examining spatial heterogeneity of uptake may be more predictive than conventional PET metrics when 
adjusting for CPFs.  Solidity quantifies how dispersed the primary and nodal disease are in a local region 
context (all stage III patients).  COM energy quantifies the uniformity of the SUV values within the 
primary tumor while taking into account the spatial orientation of the voxels.  The COM energy metric is 
calculated by determining the probabilities for different voxel-adjacent voxel-pairs within the tumor, 
squaring these values, and summing them together.  Therefore, a completely uniform tumor would have a 
COM energy of 1 while a heterogeneous tumor where few adjacent voxels have the same SUV value 
would have a COM energy value that is very small.         
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Use of QIFs from routinely obtained images has the potential to provide value to clinical practice 
without any added expense or radiation exposure.  Pretreatment risk stratification could enable clinicians 
to deliver more patient-specific treatment tailored to individual risk.  Particularly in advanced NSCLC 
patients, accurate predictions might aid in determining the appropriate level of treatment aggressiveness 
and maintaining as much of a patient’s quality of life as possible.  Additionally, more accurate prediction 
models could ensure more balanced and/or appropriate treatment arms in prospective trials.   
Prediction models that include QIFs have been shown to have significant potential; however, a 
few limitations should be noted.  First, most of the evidence for the prognostic ability of QIFs (including 
this study) comes from retrospective reviews and not from prospective assessment.  Additionally, in order 
to generate sizable cohorts, several studies have used patient data acquired on a variety of scanners 
implementing various/outdated reconstruction parameters (e.g., differing voxel sizes or use of 2D 
reconstruction).  Recently, literature has emerged that found these differences have a significant impact 
on the reproducibility of the extracted QIFs.53–56 Leijenaar et al. have analyzed the reproducibility of QIFs 
using test-retest scans and specifically found that the COM energy feature had an intra-class correlation 
coefficient (this is the same as the CCC used in this work) of 0.96.   
However, our work found using “pseudo” test/retest scans that COM energy had a much lower 
CCC (0.56). This result suggests that this feature may be “portable” enough to have broad implementation 
but normalizing acquisition/reconstruction parameters may be beneficial. Specific Aim 2.2 found that a 
majority of features are reasonably reproducible even when using scans separated by time, reconstruction, 
scanner type, etc. Numerous publications suggest that standard quantitative FDG-PET features, such as 
SUVmean, SUVmax, etc., are variable across scanners/institutions.57–59 Therefore, the observation that QIFs 
were reasonably reproducible in our “pseudo” test/re-test cohort was initially surprising considering the 
nonhomogeneous nature of the protocols/scanners used. The reason for this observation was found to be 
differences in the metric used to define reproducibility.  For instance, the CCC index for SUVmean for all 
test/re-test pairs was 0.85, which is viewed as reproducible.  However, the average absolute percent 
difference for SUVmean was 21%, which is similar to observations in the literature.57       
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Tumor delineation on PET images is also less than straightforward.  Many delineation methods 
exist such as manual contouring, value thresholding, percentage thresholding, and a variety of other semi-
automated techniques.  This work used a semi-automated gradient technique because a review by Werner-
Wasik et al. found this method to be the most robust in terms of accuracy and consistency for NSCLC 
tumors.42This study found PETedge to be superior to manual contour and thresholding due to its lower 
percent error in segmented volume and very low systematic bias. Variations in tumor delineation could 
easily influence the extracted QIFs.  
This investigation generated retrospective reconstruction datasets from a NEMA IEC phantom as 
well as patient scans. The purpose of this data was to determine feature reproducibility in a more 
controlled manner than our “pseudo” test/re-test dataset.  The phantom data did a reasonable job of 
replicating the reproducibility seen within the patient reconstructions.  A majority of features were found 
to have a high ratio of the standard deviation of clinical patient QIFs to standard deviation of QIFs from 
phantom/patient reconstructions. COM correlation and homogeneity performed the poorest, having 
standard deviation ratios of approximately two or less. These features may not be sufficiently robust to 
quantify features from a variety of sources due to their sensitivity to changes in reconstruction. While the 
ratio of standard deviations may seem high, it is important to realize that the potential for substantial 
changes still exists. Our investigation only evaluated reconstruction parameters in routine clinical use. 
Images generating using reconstruction parameters outside the limits of those investigated may still 
generate QIF values that vary substantially from images generated using more routine reconstructions. 
One should also consider the implications of using a ratio of standard deviations between patient data and 
reconstructed data. Substantial percent changes in a particular feature can exist (e.g., SUV max change of 
30%) and still yield a reasonably high ratio of standard deviations. The standard deviation ratio takes into 
account the variance seen within patients and therefore a 30% change may not be substantial when taking 
into account the range of values seen clinically.  While changes in most QIFs due to the different 
reconstruction techniques investigated appear to be minor, future studies should strive to collect imaging 
data with as limited variation in reconstructions/parameters as possible. The balance between 
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homogenizing imaging and patient numbers is something that should be considered on a project-to-
project basis. Future work determining if images can be retrospectively normalized to a particular 
baseline may prove beneficial.  
One important observation that should also be noted is that COM energy and uniformity of FDG-PET are 
very closely correlated. Since uniformity was seen to be more reproducible, it may be wise to analyze 
both COM energy and uniformity in future studies. However, uniformity was found to be more 
susceptible to changes in tumor volume than COM energy. The summary of the results for Specific Aim 1 
Hypotheses (2.1-2.3) are shown in Table 19. 
Table 19. Summary of Results for Specific Aim 2 Hypotheses 
Hypothesis Result(s) 
Project 2.1 Quantify the impact of 
adding FDG-PET-based quantitative 
image features to outcome models 
containing only CPFs 
 
Likelihood Ratio Test: 
OS: p=0.007 
 
Project 2.2 Quantify the 
reproducibility of FDG-PET-based 
quantitative image features using 
“pseudo” test-retest scans 
 
12/15 (80%) of QIFs did not have a 
CCC> 0.9 
 
CCC of 2D-3D reconstruction  
(average = 0.72) vs 3D-3D (average 
= 0.93) 
Project 2.3 Quantify the 
reproducibility of FDG-PET-based 
quantitative image features using 
retrospective reconstructions of 
phantom and patient data  
 
 
3/9 (33%) of QIFs  in NEMA 
phantom and 2/9 (22%) QIFs in 
patients did not have ratio of 
standard deviations greater than 3 
  
 
This promising work has several limitations. First, retrospective data derived only from a single 
institution cohort is hypothesis generating. Proper validation using a sizeable independent cohort of 
patients is needed. Second, we originally considered 26 distinct QIFs and did not solely perform our 
analysis using the two QIFs found to predictive. However, the use of cross-validation for simultaneous 
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multivariate selection of these features should provide a better assessment of predictive model fit than re-
substitution statistics.   
The reproducibility of most FDG-PET QIFs was found to be reasonable considering the variation 
seen in features from Cohort 3. The “pseudo” test/retest analysis found reproducibility values that were 
lower than what has been previously reported in the literature. This is likely due to additional sources of 
variability such as scanner manufacturer/reconstruction methodology, scan timing, tumor growth, change 
in underlying FDG-uptake, etc., that are not present in other publications examining this issue. Feature 
variability within Cohort 3 is likely somewhere in between what was observed in the “pseudo” test/retest 
cohort and patient data using retrospective reconstructions.  
Our work provides additional data supporting the use of FDG-PET QIFs in NSCLC to the 
growing body of literature currently available.12, 21, 23, 35 Similar to our work performed in CT, the 
analyzed FDG-PET cohort from section 4.2.1 was comprised entirely of stage III patients. Kang et al. also 
investigated FDG-PET based QIFs in a cohort comprised solely of stage III NSCLC patients.21 They 
found the area under the curve of the cumulative SUV histogram (AUC-CSH) was an independent 
prognostic factor for progression-free survival, locoregional-recurrence free survival, and distant 
metastases-free survival (p < 0.05). We examined the AUC-CSH metric in section 4.2.1 but it was not 
selected using our methodology in terms of its association with patient survival. AUC-CSH was also not 
found to be associated with overall survival, local-regional control, or freedom from distant metastases on 
univariate analysis. One reason why the prognostic ability of this metric was not able to be validated 
could be that Kang et al. extensively used optimal cut-offs for AUC-CSH as well as other conventional 
prognostic factors. This type of methodology has been associated with an increase in Type I error.60 In 
addition, Tixier et al. also did not find AUC-CSH to be significant predictor of overall survival or 
recurrence free survival.23 
Other work has been performed examining the prognostic ability of FDG-PET based QIFs in 
NSCLC in patients with multiple stages.12, 23 Cook et al. investigated 4 nearest gray tone difference matrix 
features relationship to tumor response along with overall survival, progression-free survival, and local 
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progression-free survival. Tumor coarseness, contrast, and complexity were found to be significantly 
different between responders and non-responders (p < 0.05). Tumor contrast had the largest area under 
the curve for predicting tumor response (AUC = 0.82). Tumor coarseness, contrast, and complexity were 
all found to be significantly predictive of one or more of the outcomes measured. However, the 
relationship between these QIFs and patient outcomes were tested using optimal-cutoffs in a univariate 
manner. These methods could potentially be problematic and have led to overly optimistic results.     
Accurate knowledge of a patient’s prognosis is a valuable tool in medicine and particularly in 
oncology.  We demonstrated that QIFs extracted from pretreatment PET images enhance stratification of 
patients based on overall survival compared to CPFs.  Appropriate use of these models could greatly aid 
the treating clinicians and the patients themselves.  More studies need to be conducted to validate PET 
derived QIFs and determine whether these techniques could one day be implemented clinically.  
Moving forward, additional research should be conducted to standardize all aspects of feature 
analysis (such as homogenizing features extracted, feature nomenclature, feature formulas, feature 
parameters used, modeling techniques, image acquisition, etc.). This is very similar to the standardization 
needed in CT and is perhaps even more difficult. FDG-PET has scanner-based variation just like CT but 
since FDG-PET measures a biological process it has inherent biologic variation from the patient as well 
as variation stemming from the use of a radiotracer (variation injection-scan time interval, injected 
dosage, etc.). A large cohort of patients with imaging from multiple scanners, injection timings, 
reconstruction parameters, etc. would be useful in determining thFeature/methodology standardization 
analyses need to be conducted in order for large scale retrospective/prospective studies to reach their full 
potential in terms of advancing the field.     
Discussion Specific Aim 3 
We hypothesized that there would be significant relationships between some quantitative image 
features between modalities and with tumor volume, staging, and morphologic characteristics. This 
hypothesis was confirmed as significant relationships were found between some quantitative image 
features between modalities and with tumor volume, staging, and morphologic characteristics. A theme 
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throughout this work is the importance of not only determining the prognostic value of QIFs but to 
quantify their significance in addition to CPFs. Furthermore, it is important to gain an understanding of 
why these features seem to be prognostic and if features from different modalities are related. FDG-PET 
based QIFs identified in Specific Aim 2 were significantly correlated with the LOG_Average extracted 
from CE-CT (p < 0.05). Solidity as measured on FDG-PET was also significantly correlated with CE-CT 
uniformity (p < 0.05).  A variety of significant associations were also seen between QIFs (from FDG-PET 
and CE-CT) and CPFs such as volume and staging and morphologic characteristics, such as visualized 
necrosis and vascularity. 
The QIFs extracted in Specific Aims 1 and 2 seem to be related not only to one another in some 
capacity but also to CPFs and morphologic characteristics of tumors. The fact that QIFs have associations 
with CPFs is not a surprise nor does it invalidate our findings since QIFs were shown to have prognostic 
potential beyond CPFs. However, it is important to be cognizant of the fact that these relationships do 
exist in order to not overstate possible conclusions.   
One of the more interesting results from Specific Aim 3 is the identification of a relationship 
between FDG-PET-based QIFs and the LOG_Average and Uniformity QIFs extracted from CE-CT. This 
relationship links features from a predominantly anatomical imaging modality (CT) to a functional 
imaging modality (FDG-PET). The linkage from anatomical to functional supports a hypothesis that 
morphologic characteristics/phenotypes of tumors can relate to underlying functional/biologic 
phenotypes. However, while some associations were statistically significant the correlation coefficients 
were quite low. To our knowledge, there is only one publication in the literature that suggests that two 
different imaging modalities may be related in terms of their extracted QIFs.10 However, this was done in 
non-contrasted CT and was not done using factors found to be significant in any sort of outcome analysis.  
We were able to demonstrate that morphologic characteristics of tumors such as enhancing 
vasculature, necrosis, and air within tumor cavitation can influence the two examined QIF measurements 
(LOG_Average and histogram based uniformity). LOG_Average was found to be influenced by these 
morphologic characteristics of tumors to a greater extent than histogram uniformity. Tumors with necrosis 
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and enhancing vasculature demonstrated an increase in LOG_Average (p < 0.0001 and p < 0.0001, 
respectively) but did not have the same magnitude of impact on histogram uniformity (p=0.19 and p = 
0.03, respectively). The presence of air within cavitated tumors led to a decrease in uniformity (p = 
0.0001). Tumor morphologic characteristics, such as  presence of enhancing vasculature and necrosis, 
may contribute to the underlying reason why QIFs appear to be prognostic in a variety of tumors. Our 
results demonstrated a significant difference in QIF values between tumors with and without air within 
cavitated tumors, necrosis, and enhancing vasculature. 
Excluding morphologic characteristics was found to alter the QIFs measured from tumors; 
however, this was only significant when examining LoG Average and excluding tumors with a large 
volume of vessels. Excluding air, necrosis, and/or vessels from the analyzed contour did not impact the 
resulting QIF values substantially compared to examining only “tumor tissue”. The tumor tissue alone 
appeared to explain a vast majority of the resulting QIF values for LOG_Average and histogram 
heterogeneity compared to analyzing the entire tumor (R-squared = 0.92 and 0.96, respectively).  
At first glance this result may seem inconsistent; however, this could be due to the interaction 
between these morphologic characteristics and the tumor tissue itself. For example, the presence of 
enhancing vessels or necrosis within the tumor may lead to heterogeneity in contrast uptake within the 
tumor tissue causing more “edges” being measured by LOG_Average. This can be observed in Figure 1. 
Tumors with higher than average volume of vessels (black points in Figure 33) have higher values of 
LOG_Average than tumors with lower than the average volume of vessels (gray points in Figure 33) (p < 
0.05). The same pattern can also be observed in Figure 33 for necrosis (p < 0.05). These types of 
processes may  contribute to the values obtained from QIFs. 
 Literature attempting to determine what is fundamentally being measured from QIFs from CT in 
NSCLC or what tissue-related factors may influence QIF measurement is scant. Ganeshan et al. and van 
Gomez et al. both examined the relationship between CT-based QIFs and SUV features from FDG-
PET.10, 35 Ganeshan et al. found that coarse texture features correated with mean tumor SUV and van 
Gomez et al. found correlations between a variety of CT-based QIFs and FDG-PET features. A separate 
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publication from Ganeshan et al. established relationships between CT-based QIFs and hypoxia markers 
from FDG-PET and pathology.14 Additionally, Aerts et al. observed that certain QIF clusters are 
associated with primary tumor stage, overall stage, and histology. Aerts et al. also found that the QIFs 
incoporated into their “radiomics signature” were found to have high normalized enrichment scores in 
their analysis of gene expression.8 However, a majority of these publications were performed in non-CE-
CT whereas our study was performed using contrast enhanced scans.  
The correlated nature between CE-CT and FDG-PET QIFs suggests that analysis of both 
modalities in tandem has the potential to provide additional prognostic information.  
When designing the autosegmentation algorithms, we found that the most difficult portion was 
differentiating necrosis from tumor tissue. The Hounsfield unit values of air and enhancing vessels are 
substantially different from tissue and therefore amenable to a simple thresholding approach. However, 
tumor necrosis contains Hounsfield unit values that are only slightly lower than the rest of the tumor 
tissue. Tumor necrosis is more easily identified on FDG-PET than on CT (see Figure 3). Therefore, 
establishing that both autosegmentation methods on both image types resulted in similar values of 
necrosis volume and percentage of necrosis within the tumor is encouraging and supports the accuracy of 
segmentation on CE-CT (CCC = 0.85 and 0.76, respectively). The decrease in CCC value between 
necrosis volume and percentage of tumor containing necrosis could be due to variability in delineating the 
tumor itself on CT versus PET and not the autosegmentation. Furthermore, necrotic regions with low 
FDG-avidity may not always appear on CE-CT as having lower Hounsfield unit values which would 
cause discrepancies in quantifying necrosis volume. Overall, the agreement seen between the two 
methodologies was reasonable based on their CCC values and supports the accuracy of CE-CT 
autosegmentation.   
Quantifying and relationships and/or correlations between QIFs from different modalities, CPFs, 
and morphologic characteristics are needed in order to increase our understanding of how and why QIFs 
appear to provide prognostic information. Furthermore, these types of studies are of paramount 
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importance if QIFs are ever to be optimized in terms of their preprocessing and method of quantification. 
The summary of the results for Specific Aim 3 Hypotheses are shown in Table 20. 
Table 20. Summary of Results for Specific Aim 3 Hypotheses 
Hypothesis Result(s) 
Project 3.1. Quantify correlations 
between prognostic FDG-PET-based 
and CECT-based quantitative image 
features 
 
See Table 15 
Project 3.2. Quantify if relationships 
exist between CE-CT-based and FDG-
PET-based quantitative image features 
with tumor volume and TNM staging 
 
 
See 
 
 
Figure 28,  
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Figure 29 
Project 3.3. Quantify if there are 
correlations between FDG-PET-based 
quantitative image features, CECT-
based quantitative image features, and 
morphologic characteristics (vessels, 
necrosis, air cavities, etc.) 
 
 
See Figure 30, Figure 31 
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While this work is a good initial step, there are several limitations. This was done retrospectively 
using only 78 patients with both a CE-CT and FDG-PET taken at a single institution. This does not 
address whether significant associations/correlations would be observed across a wider array of patients, 
scanners, etc. Statistical significance in terms of correlation or separation of groups also does not 
necessarily translate to clinical significance. For instance, while LOG_Average and COM Energy were 
found to be significantly correlated, this does not imply that one could use these features interchangeably 
or that the prognostic value of one feature is comparable to another.  
While we believe our segmentation methodology to be sufficiently robust due to the correlation 
of necrosis volumes between CT and FDG-PET segmentations, further validation of its accuracy would 
be useful. Possible avenues to validate this segmentation would be to consult a radiologist for their 
opinion on segmentations across a range of patient tumors or examine pathology from excised lesions. In 
addition, enhancing the autosegmentation to be more robust to image artifacts, alternative reconstruction 
filters (i.e. standard versus lung versus bone), and non-contrasted scans would increase its utility. As the 
reconstructions rely heavily on HU cutoffs, the ability to adapt these cutoffs on an image-to-image basis 
may also improve its accuracy.    
 
Discussion Specific Aim 4 
We hypothesized that significant FDG-PET-based based quantitative image features found in 
Specific Aim 2 would allow for identification of sub-cohorts that will demonstrate a significant 
stratification of patients based on radiation dose. This hypothesis was confirmed as the significant FDG-
PET-based based quantitative image features (COM energy and solidity)allowed for identification of sub-
cohorts that demonstrated a significant survival stratification of patients based on radiation dose. 
Quantitative image features from CT and PET have been shown to be prognostic in a variety of solid 
tumors including NSCLC.12, 21, 23, 25  To our knowledge, this work is the first to examine the possible 
influence that these factors could have on modifying treatment. This study found that there was no 
difference in overall and progression free survival between patients being treated with 74Gy vs 60-70Gy 
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when examining the entire cohort.  When examining subgroups of our cohort based on values of QIFs, we 
found that dose escalation benefits those with high values of COM energy and solidity (i.e. those who 
have a higher predicted survival based on our previous work) and is detrimental to those with low values 
of COM energy and solidity. We found that receiving 74Gy versus 60-70Gy was an independent 
prognostic factor both overall survival (high value QIFs: p = 0.012, low value QIFs: p = 0.02) and 
progression free survival (high value QIFs: p = 0.015, low value QIFs: p = 0.025) in a multivariate Cox 
proportional hazards model. 
The literature is conflicting whether or not escalating dose yields an improved survival in patients 
with NSCLC. It has been suggested that an increase in the delivered radiation dose may improve patient 
survival in NSCLC.61RTOG 0617 examined whether dose escalation improved survival in stage III 
NSCLC patients treated with chemoradiation.62 This study found that treating to 74Gy versus 60Gy led to 
an increased incidence of grade 3 pneumonitis was detrimental to patient survival at one year (70.4% 
versus 81%, respectively). The reasons for these surprising results are the subject of intense debate.63 
There has been the suggestion that patient heart dose could be responsible for the reduced survival.  
Speirs et al found that cardiac dosimetric parameters such as mean/max heart dose were significant using 
univariate analysis for overall survival but this association was not seen when using multivariate 
techniques adjusting for factors accounting for tumor volume.64  However, a study by Liao et al found that 
the use of IMRT led to an improvement in overall survival compared to 3D conformal radiation therapy 
(3D-CRT) (p = 0.039).65 One could hypothesize that this may have been due to the dosimetric 
improvement allowed by IMRT compared to 3D-CRT in the cardiopulmonary structures. In our study 
comprised almost exclusively of IMRT patients, we did not observe a survival difference between those 
treated to at least 74Gy versus 60-70Gy. It is quite apparent that patient survival is contingent upon a 
multifactorial process and not purely radiation dose. In order to optimize treatment for patients, it would 
be advantageous to know if certain populations of stage III NSCLC are more likely to benefit from 
escalating radiation treatment dose. 
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The present work was able to demonstrate that subgroups with certain values of disease solidity 
and primary COM energy can yield significantly different survival rates based on the use of dose 
escalation. Figure 35 and Figure 37 illustrate that these observations were not obtained by merely 
selecting a subgroup in which a survival difference was seen but that an overall trend is evident regarding 
the impact of dose escalation with high/low values of these two QIFs.  It should also be noted that since 
we chose different percentile cutoffs for the dashed outline cells in Figure 35 and Figure 37, there are 
patients (4) that are in both figures.  This was done merely to display the concept with a reasonable 
sample size in each plot.  We also could have displayed subgroups where the cutoffs were the same and 
therefore there would be no patient overlap.  For example, using the values of 45% COM energy and 55% 
solidity in both Figure 35 and Figure 37, the separation would be significant (p < 0.05) for high/low 
values of QIFs in terms of overall and progression free survival however this would only yield sample 
sizes of 42 and 52 patients, respectively. The summary of the results for Specific Aim 4 Hypothesis are 
shown in Table 21. 
Table 21. Summary of Results for Specific Aim 4 Hypotheses 
Hypothesis Result(s) 
Project 4.1. Assess whether 
significant PET-based quantitative 
image features relate to a difference in 
patient survival for those treated with 
an escalated radiation dose   
 
 
See Figure 35, Figure 36, 
Figure 37, Figure 38 
 
While the results of our work are interesting and have the potential to allow physicians to better 
select patients for dose escalation, there are several limitations.  First and foremost this study is 
retrospective in nature and therefore has all the limitations that are associated with retrospective studies 
such as possible selection biases, attrition bias, methodological changes, etc.  Our cohort also had a 
mixture of patients treated with both proton and photon therapies whereas most studies examining dose 
escalation are comprised of patients treated with photon therapy. Due to the retrospective nature and 
variations in patient treatment within this study it should be seen exclusively as hypothesis generating 
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work. In the future, we hope to extract dosimetric and toxicity data from our patients to determine if any 
trends exists relating to radiation dose and whether these metrics could also be useful in better selecting 
patients for treatment. 
The use of pretreatment QIFs to better select patients for different treatments would be a 
substantial advance in how radiation oncologists treat patients.  We demonstrated that the use of QIFs 
from pretreatment FDG-PET scans in stage III NSCLC patient’s scans may allow clinicians to better 
predict who would benefit from a higher radiation dose. Further work is needed in order to validate these 
findings and better understand what factors influence which patients should be treated to a standard or 
escalated dose.  
There are numerous limitations of this work that need to be considered. More variation in feature 
values could be obtained if images were expanded to include various manufacturers, reconstruction 
parameters, etc.  A large, independent cohort would be needed to fully validate the findings from this 
work and further exploration is needed into the applicability of the metrics across institutions.  
As echoed in the previous discussion sections, feature/methodology standardization is needed in 
order to properly put these results into context and potentially validate their results. A future study 
confirming these results as well as identifying a specific cutoff of both solidity and COM energy should 
be performed before any attempt of prospective assessment.  
Discussion Overall 
Almost all previous studies examining the relationship of QIFs to patient outcome are performed 
in patients staged differently according to AJCC staging. Stratifying patients of the same stage is 
fundamentally more difficult than stratifying patients of different stages for a couple of reasons: 1. There 
will be inherently more variation in terms of patient outcome for patients of various stages and 2. Patients 
of different stages are frequently accompanied by differences in non-cancer related prognostic factors 
such as performance status and comorbidities. Models capable of stratifying patients who are 
homogeneously staged may also be more clinically useful as different stages of disease frequently dictate 
different treatment courses.  Every effort was made to try and quantify the improvement that QIFs can 
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make to outcome models when adjusting for an extensive list of CPFs. Furthermore, proper validation, 
whether using cross-validation or independent cohorts, was implemented whenever possible. A majority 
of studies in the literature do not comprehensively investigate the added benefit of QIFs but merely 
examine their impact alone or adjusting for 1-2 CPFs such as primary tumor volume or TNM staging. 
Most publications also only focus on features relating to the primary tumor and disregard information 
from nodal disease, which has been shown to relate to patient survival.4, 66 Numerous issues exist when 
using re-substitution statistics or optimal cut-offs and these issues permeate through the existing 
literature.    
Some may argue that, for those with a poor predicted prognosis, this knowledge is usually not 
beneficial since patients are already receiving the maximum tolerable treatment.  I would argue that 
treatment optimization does not necessarily equate to treatment escalation.  In some instances, perhaps de-
escalation of treatment and initiation of early palliative care may provide the best care for the patient.  An 
accurate prognosis would also be beneficial to patients and their caregivers.  Those identified as having a 
poor prognosis may be better equipped to make decisions regarding palliative versus definitive treatment 
and the role of hospice care. Section 4.4.1 found that QIFs may be potentially useful in modifying 
treatment for identified patients. This modification of treatment was shown to include both potential 
escalation and de-escalation in terms of ultimately providing patient benefit. 
The major message from this work is that many factors can and do contribute to patient 
outcome/survival. This work explored not only novel QIFs but also CPFs and these factors are only the 
tip of the iceberg. Other indicators, such as genetics, social factors, blood-based markers, etc., all may 
potentially play a role in determining outcome.  Furthermore, the cohort of patients being analyzed also 
plays a significant role in the ultimate findings. In our work, for example, the role of GTV in the CE-CT 
(Cohort 2) versus FDG-PET (Cohort 3) was found to be drastically different even when these patients 
were extremely similar in terms of CPFs. These prognostic discrepancies in basic CPFs really highlight 
the need of performing these types of analyses on extremely large patient cohorts. 
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There is a desperate need for the development of large-scale cohorts that contain not only patient 
clinical data but patient imaging, pathology, and genetics. A big data approach to the field of quantitative 
image analysis (a.k.a. radiomics) would be a tremendous advance. The use of natural language processing 
for efficient extraction of patient clinical data, pathology, and genetics would increase the ease of 
database construction. Automated workflows for extracting images from radiation treatment planning 
systems and/or PACs followed by robust and validated disease segmentation algorithms should be 
employed in the future to facilitate high throughput data collection. Ideally, the use of a single 
quantitative analysis software would be ideal but simply standardizing feature nomenclature and 
calculation across platforms would be a good first step. Databases exist that contain a portion of the 
required information such as the Surveillance, Epidemiology, and End Results (SEER) program. SEER 
could be used as a model in the generation of future databases with more comprehensive information 
needed to truly develop and investigate aspects personalized patient care. 
Ultimately, outcome model development is an extremely difficult process that requires 
knowledge in a variety of areas. Researchers need to be familiar with both the medical and 
quantitative/analysis sides of the problem if they hope to conduct work that may one day translate into 
clinical benefit. The aforementioned work found encouraging results in terms of analyzing the prognostic 
value of QIFs from pretreatment CT and FDG-PET scans in stage III NSCLC patients undergoing 
definitive radiation therapy but has many potential caveats and drawbacks as discussed previously. This 
work has the potential to one day improve the quality of care for these patients and the processes 
described are translatable to other stages and/or tumor types. Additional investigation and/or optimization 
regarding standardization of image acquisition(s), quantification methods, and statistical 
analysis/validation are necessary and encouraged in order to realize the maximum potential of using 
image-based features for improving personalized cancer care.   
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Appendix A: Matlab Code for CE-CT Autosegmentation 
This function was used in the work performed in section 4.3.3 Results for Project 3.3: Quantify if 
there are correlations between FDG-PET-based quantitative image features, CECT-based quantitative 
image features, and morphologic characteristics (vessels, necrosis, air cavities, etc.) in order to segment 
the morphologic characteristics. 
function [Air_out,Necrosis_out,Tissue_out,Vessel_out]=TissueSeg3(CDataSetInfo) 
disp_img = 0; 
Air_bounds=[0 950];%%%white 
Tissue_bounds = [1020 1120];%%%blue 
Vessel_bounds = [1120 2000];%%%green 
  
%%%%%%%%%%%%%%%%% 
%%%%Initiation of Outputs%%%% 
%%%%%%%%%%%%%%%%% 
Tissue_out = 
zeros(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2),size(CDataSet
Info.ROIImageInfo.MaskData,3)); 
Vessel_out = 
zeros(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2),size(CDataSet
Info.ROIImageInfo.MaskData,3)); 
Air_out = 
zeros(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2),size(CDataSet
Info.ROIImageInfo.MaskData,3)); 
  
  
disp('1: Identifying necrotic regions') 
%%%%%%%%%%%%%%%%%% 
%%%Identify Necrosis in 3D%%%% 
%%%%%%%%%%%%%%%%%% 
Necrosis_use = necrosis3d(CDataSetInfo); %Separate Code (see Appendix B) 
disp('2: Finished necrosis region growing') 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%Identify Air,Vessels, Tissue on each 2D slice%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
for slice = 1:size(CDataSetInfo.ROIBWInfo.MaskData,3); 
    IMG=CDataSetInfo.ROIImageInfo.MaskData(:,:,slice); 
    Mask = CDataSetInfo.ROIBWInfo.MaskData(:,:,slice); 
    filt = fspecial('gaussian', [3 3],0.7); 
    TumorTest1 = roifilt2(filt,IMG,Mask); 
    if isempty(TumorTest1) 
        TumorTest1 = zeros(size(Mask)); 
    end 
    Mask(IMG<875) = 0; 
    Maskfill=imfill(Mask,'holes'); 
     
    %%%%%%%%%%%%%%%%%%% 
    %%%%Identify Air and Vessels%%%% 
    %%%%%%%%%%%%%%%%%%% 
    TumorTest1 = double(TumorTest1).*double(Maskfill); 
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    TumorTestinit = double(IMG).*double(Maskfill); 
    Air_use=TumorTestinit>Air_bounds(1) & TumorTestinit<=Air_bounds(2); 
    Air_use = imerode(Air_use,ones(2));Air_use = imerode(Air_use,ones(2)); 
    Air_use = imdilate(Air_use,ones(2));Air_use = imdilate(Air_use,ones(2)); 
    Air_use=imfill(Air_use,'holes'); 
    Vessel1=TumorTest1>Vessel_bounds(1) & TumorTest1<=Vessel_bounds(2); 
    Vessel_use=double(bwareaopen(Vessel1,2)); 
    %%%%%%%%%%%%%%%% 
    %%%%Identify Tissue%%%%% 
    %%%%%%%%%%%%%%%% 
    Tissue1=TumorTest1>Tissue_bounds(1) & TumorTest1<=Tissue_bounds(2); 
    Tissue_use=double(bwareaopen(Tissue1,5)); 
    Tissue_use=abs(bwareaopen(abs(Tissue_use-1),20)-1); 
    Tissue_use = Tissue_use - (Tissue_use&(Air_use|Vessel_use|Necrosis_use(:,:,slice))); 
    %%%%%%%%%%%%%%%%% 
    %%%% Define the outputs%%%% 
    %%%%%%%%%%%%%%%%% 
    Vessel_out(:,:,slice) = Vessel_use; 
    Necrosis_out = Necrosis_use; 
    Air_out(:,:,slice) = Air_use; 
    Tissue_out(:,:,slice) = Tissue_use; 
end 
disp('3: Identified Air and Vessels') 
%%%%%%%%%%%%%%%%%%%%%%% 
%%%%Check that Necrosis is Bounded%%%% 
%%%%%%%%%%%%%%%%%%%%%%% 
for i = 1:size(CDataSetInfo.ROIBWInfo.MaskData,3); 
    IMG=CDataSetInfo.ROIImageInfo.MaskData(:,:,i); 
    Mask = CDataSetInfo.ROIBWInfo.MaskData(:,:,i); 
    Mask(IMG<875) = 0; 
    Maskfill=imfill(Mask,'holes'); 
  
     
     
    Regions=bwlabel(Necrosis_use(:,:,i)); 
    Seg_out = 3*Vessel_out(:,:,i)+Necrosis_out(:,:,i)+2*Air_out(:,:,i)+4*Tissue_out(:,:,i); 
    for r = 1:max(Regions(:)) 
        region = Regions==r; 
        SE = strel('disk', 4); 
        Rdilated = imdilate(region,SE); 
        perim = bwperim(Rdilated); 
        [num,~]=hist(Seg_out(perim==1),[0,1,2,3,4]); 
        if(sum(num(2:5))/sum(num(:))>0.75) 
            disp(sum(num(2:5))/sum(num(:))) 
        else 
            Necrosis_use(:,:,i)=Necrosis_use(:,:,i)-region; 
            Tissue_out(:,:,i) = Tissue_out(:,:,i)+region; 
        end 
    end 
    Tissue_out(:,:,i) = imfill(Tissue_out(:,:,i)); 
end 
disp('4: Checked that necrosis met constraints') 
Necrosis_out = Necrosis_use; 
Tissue_out = Tissue_out - (Tissue_out&(Air_out|Vessel_out|Necrosis_out)); 
  
%%%%%%%%%%%%%%%%%%%%% 
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%%%%Initialize Colors for Display%%%% 
%%%%%%%%%%%%%%%%%%%%% 
Red = zeros(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2),3); 
Green = Red; 
Blue = Red; 
White = Red; 
Red(:,:,1) = ones(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2)); 
Green(:,:,2) = ones(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2)); 
Blue(:,:,3) = ones(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2)); 
White(:,:,1) = ones(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2)); 
White(:,:,2) = ones(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2)); 
White(:,:,3) = ones(size(CDataSetInfo.ROIImageInfo.MaskData,1),size(CDataSetInfo.ROIImageInfo.MaskData,2)); 
  
%%%%%%%%%%%%%%%%%%%%% 
%%%%Code for Displaying Results%%%% 
%%%%%%%%%%%%%%%%%%%%% 
if(disp_img==1) 
    for slice = 1:size(CDataSetInfo.ROIBWInfo.MaskData,3); 
        image = slice; 
        IMG=CDataSetInfo.ROIImageInfo.MaskData(:,:,image); 
        Mask = CDataSetInfo.ROIBWInfo.MaskData(:,:,image); 
        I = double(IMG).*double(Mask); 
        figure(1); subplot(1,2,1); 
        figure(1); imagesc(I,[900 1300]); colormap(gray); hold on; 
        figure(1); type1 = imagesc(Red); 
        set(type1, 'AlphaData', Necrosis_out(:,:,slice)*0.2); 
        figure(1); type2 = imagesc(Green); 
        set(type2, 'AlphaData', Tissue_out(:,:,slice)*0.2); 
        figure(1); type3 = imagesc(Blue); 
        set(type3, 'AlphaData', Vessel_out(:,:,slice)*0.2); 
        figure(1); type4 = imagesc(White); 
        set(type4, 'AlphaData', Air_out(:,:,slice)*0.5); hold off; 
        subplot(1,2,2); 
        imagesc(I,[900 1300]); 
        pause(1) 
         
    end 
else 
    disp('display off') 
end 
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Appendix B: Matlab Code for CE-CT Necrosis Identification 
This is a sub-function used in Appendix A: Matlab Code for CE-CT Autosegmentation. 
function Necrosis_use=necrosis3d(CDataSetInfo) 
disp_img =0;%set to zero in IBEX 
  
%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%Identify Initial Image and Mask Data%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%% 
IMG=CDataSetInfo.ROIImageInfo.MaskData; 
IMGinit = IMG; 
Maskfill = CDataSetInfo.ROIBWInfo.MaskData; 
Mask_noair = Maskfill; 
%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%removal of air not encapsulated by tumor%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%% 
Maskfill(IMGinit<975) = 0; 
Mask_noair(IMGinit<950)=0; 
for i = 1:size(CDataSetInfo.ROIImageInfo.MaskData,3); 
Maskfill(:,:,i) = imfill(Maskfill(:,:,i),'holes'); 
end 
IMGinit(Maskfill==1 & IMGinit<975)=1005;%Fill encapsulated air with 1005 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%Establish guess for necrosis based off threshold and filtered image%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
Necr_bounds = [975 1020]; 
for i = 1:size(CDataSetInfo.ROIImageInfo.MaskData,3); 
    filt = fspecial('gaussian',[5 5],1.5); 
    if max(Maskfill(:,:,i))>0 
    IMGinit(:,:,i) = roifilt2(filt,IMGinit(:,:,i),Maskfill(:,:,i)); 
    else 
    end 
end 
use=IMGinit.*uint16(Mask_noair); 
N_guess = (use>Necr_bounds(1)).*(use<=Necr_bounds(2)); 
for i = 1:size(CDataSetInfo.ROIImageInfo.MaskData,3); 
    N_guess(:,:,i) = imfill(logical(N_guess(:,:,i)),'holes'); 
end 
SE = strel('disk', 2); 
N_guess = imdilate(imerode(N_guess,SE),SE); 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%Determine if multiple regions within the guess exists, analyze largest%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
if(max(N_guess(:))>0) 
    [L,num] = bwlabeln(N_guess); 
    [value,~]=hist(nonzeros(L),1:num); 
    biggest_region = find(max(value)==value); 
    Necr_cent = L==biggest_region(1); 
    N=BWcentroid(Necr_cent); 
    disp('Into region growing') 
    [~,Necrosis_use] = regionGrowing(use, [N(2) N(1) N(3)],35,[],false); 
    disp('Out of region growing') 
    for i = 1:size(CDataSetInfo.ROIImageInfo.MaskData,3); 
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        Necrosis_use(:,:,i)=imerode(Necrosis_use(:,:,i),ones(3)); 
        Necrosis_use(:,:,i) = bwareaopen(Necrosis_use(:,:,i),50); 
        Necrosis_use(:,:,i) =imdilate(Necrosis_use(:,:,i),ones(3)); 
        Necrosis_use(:,:,i) = bwareaopen(Necrosis_use(:,:,i),50); 
    end 
else 
    Necrosis_use = zeros(size(N_guess,1),size(N_guess,2),size(N_guess,3)); 
end 
  
%%%%Necrosis_use is the output of this function%%%% 
  
 
 
%%%%%%%%%%%%%%%% 
%%%%Display Results%%%% 
%%%%%%%%%%%%%%%% 
  
R = zeros(size(IMG,1),size(IMG,2),3); 
R(:,:,1) = 1; 
if(disp_img==1)%This is set to 0 within IBEX and therefore not executed 
    for i = 1:size(CDataSetInfo.ROIImageInfo.MaskData,3); 
        figure(1); 
        subplot(1,3,1);imagesc(use(:,:,i),[900 1300]);colormap(gray);  
        subplot(1,3,2);imagesc(IMG(:,:,i),[900 1300]);colormap(gray);  
         subplot(1,3,3);imagesc(IMG(:,:,i),[900 1300]);colormap(gray); hold on 
        subplot(1,3,3);red=imagesc(R); 
        set(red, 'AlphaData', Necrosis_use(:,:,i)*0.2); 
        pause(1); hold off 
    end 
end 
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Appendix C: R Code for Cross-Validation Technique 
###Used for both CT and PET analyses### 
###Import data### 
datapath <- "Y:/NSCLC_Texture/November2014/" 
data <- read.csv(paste(datapath,"PETall_HDFU.csv", sep = ""), header = T) 
 
###Load Required Packages### 
library("penalized") 
library("survival") 
source("http://bioconductor.org/biocLite.R") 
biocLite("survcomp") 
library("survcomp") 
require(survival) 
require(survcomp) 
require(MASS) 
require(penalized) 
require(pensim) 
require(Hmisc) 
 
###Custom functions which may or may not be used### 
source('Y:/NSCLC_Texture/Jul2014/make_formula.R', echo=FALSE) 
 
####set parameters###### 
out = "surv"  #outcome of interest (e.g. surv,dm,loco) 
out_time <- eval(parse(text = paste("data$",out,"rtstartmos",sep = ""))) 
out_stat <- eval(parse(text = paste("data$",out,"stat",sep = ""))) 
 
 
###Initialize/reformat various covariates#### 
lorig<-dim(data)[2] 
Solidity<-data$MVolume/data$MConvexHullVolume3D 
data[,lorig+1]<-Solidity 
names(data)[lorig+1]<-"Solidity" 
 
data[,lorig+2]<-data$Total.Dose/100*(1+(as.numeric(as.character(data$D.fx))/100)/10) 
names(data)[lorig+2]<-"BED" 
data$BED[which(data$D.fx=="split")]=92.1 
 
data[,lorig+3]<-data$PGlobalStd/data$PGlobalMean 
names(data)[lorig+3]<-"COV" 
 
data[,lorig+4]<-data$PNecrVolume>0.5 
names(data)[lorig+4]<-"NEC" 
 
data[,which(names(data)=="MVolume")]<-log2(data$MVolume) 
data[,which(names(data)=="MConvexHullVolume3D")]<-log2(data$MConvexHullVolume3D) 
data[,which(names(data)=="GTV")]<-log2(data$GTV) 
data[,which(names(data)=="PVolume")]<-log2(data$PVolume) 
data[,which(names(data)=="PSurfaceArea")]<-log2(data$PSurfaceArea) 
data[,which(names(data)=="MSurfaceArea")]<-log2(data$MSurfaceArea) 
 
data$ECOG<-as.ordered(as.numeric(data$ECOG>0)) 
data$KPS<-as.factor(as.numeric(data$KPS<90)) 
data$Smoking<-as.ordered(data$Smoking) 
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data$PY<-as.numeric(data$PY) 
data$Hist<-as.factor(data$Hist) 
data$Tstage<-as.factor(as.numeric(data$Tstage>2)) 
data$Nstage<-as.factor(as.numeric(data$Nstage>1)) 
data$Overall<-as.factor(as.numeric(data$Overall)) 
data$Induction<-as.factor(data$Induction) 
data$PGlobalStd<-as.numeric(data$PGlobalStd) 
data$Gender<-as.numeric(data$Gender) 
data$Solidity[data$Solidity>1]<-1 
 
###Conditions for Inclusion#### 
rule1<-data$PVolume>log2(5) 
data<-data[which(rule1),] 
out_time <- out_time[which(rule1)] 
out_stat <- out_stat[which(rule1)] 
 
###select clinical and QIFs### 
set.seed(5126) 
vars<-names(data)[c(3:13,17,67:114,lorig+1,lorig+2,lorig+3,lorig+4)] 
evaluate_clin<-select.list(vars,multiple=TRUE,graphics=TRUE,preselect=vars[c(1:3,5:12,62)]) 
evaluate_all<-select.list(vars,multiple=TRUE,graphics=TRUE,preselect=vars[c(1:3,5:64)]) 
 
###Initialize Cross-Validated scores### 
predPENsurv_all <- rep(0,length(out_stat)) 
predPENsurv_clin <- rep(0,length(out_stat)) 
predPENscore_all <- rep(0,length(out_stat)) 
predPENscore_clin <- rep(0,length(out_stat)) 
termsOPTouter_clin = NULL 
termsOPTouter_all = NULL 
 
pb<-winProgressBar("SVM-Progress Bar","Initializing",0,100,0) 
 
###Start of Cross-Validation### 
for(i in 1:length(out_stat)){ 
  data_minus_fold = data[-i,] 
  out_time_temp<-out_time[-i] 
  out_stat_temp<-out_stat[-i] 
   ###L1 penalization### 
  opt_clin<-optL1(Surv(out_time_temp,out_stat_temp), penalized = 
data.matrix(data_minus_fold[evaluate_clin]),data=data_minus_fold,standardize = TRUE,trace=TRUE,fold = 10) 
  opt_all<-optL1(Surv(out_time_temp,out_stat_temp), penalized = 
data.matrix(data_minus_fold[evaluate_all]),data=data_minus_fold,standardize = TRUE,trace=TRUE,fold = 10) 
  ###predictions### 
  predPENsurv_clin[i]<-survival(predict(opt_clin$fullfit,penalized=data.matrix(data[i,evaluate_clin])),36) 
  predPENsurv_all[i]<-survival(predict(opt_all$fullfit,penalized=data.matrix(data[i,evaluate_all])),36) 
  ###determination of coefficients used in each fold### 
  coefs_clin<-names(coefficients(opt_clin$fullfit)) 
  coefs_all<-names(coefficients(opt_all$fullfit)) 
  termsOPTouter_clin<-c(termsOPTouter_clin,coefs_clin) 
  termsOPTouter_all<-c(termsOPTouter_all,coefs_all) 
  clin<-coefficients(opt_clin$fullfit) 
  tex_clin<-coefficients(opt_all$fullfit) 
  ###generation of linear predictors### 
  if(length(clin)!=0){ 
    predPENscore_clin[i]<-rowSums(t(matrix(rep(clin,1),nrow = 
length(clin)))*as.numeric(data.matrix(data[i,names(clin)]))) 
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  } 
  if(length(tex_clin)!=0){ 
    predPENscore_all[i]<-rowSums(t(matrix(rep(tex_clin,1),nrow = 
length(tex_clin)))*as.numeric(data.matrix(data[i,names(tex_clin)]))) 
  } 
   
  setWinProgressBar(pb,round(i/length(out_stat)*100),label = paste("Working on Fold",i,"of",length(out_stat),sep=' 
')) 
   
} 
 
###Calculate C-indices### 
cindex_clin<-CTindex(out_time,out_stat,-predPENscore_clin) 
cindex_all<-CTindex(out_time,out_stat,-predPENscore_all) 
 
###k-means for stratification### 
numclusters<-5 
set.seed(1) 
clin_cluster<-rep(0,length(predPENscore_clin)) 
all_cluster<-rep(0,length(predPENscore_clin)) 
clin<-kmeans(predPENscore_clin,numclusters) 
all<-kmeans(predPENscore_all,numclusters) 
for(i in 1:length(clin$centers)){ 
  clin_cluster[clin$cluster==order(clin$centers)[i]]<-i 
} 
for(i in 1:length(all$centers)){ 
  all_cluster[all$cluster==order(all$centers)[i]]<-i 
} 
 
###Plot of KM curves for generated clusters from CV linear predictors### 
layout(matrix(c(1,2,3,3),2,2,byrow=TRUE),heights=c(2,1))       
km.coxph.plot(formula.s=Surv(out_time,out_stat) ~ clin_cluster, data.s=data,x.label="Time (months)", 
y.label="Overall Survival Probability", main.title="Overall Survival\n Conventional Prognostic Factors including 
GTV", leg.pos= "topright", leg.text=paste(c("Lowest Risk     ","Low/Medium Risk       ","Medium Risk     
","Medium/High Risk      ","Highest Risk     ")),leg.inset=0, .col=c("black","darkgray"), .lty=c(1,1,3,3,4),.lwd = 
c(4,5,5,5,6), show.n.risk=TRUE, n.risk.step=6, xlim = c(0,42),verbose=TRUE) 
km.coxph.plot(formula.s=Surv(out_time,out_stat) ~ all_cluster, data.s=data,x.label="Time (months)", 
y.label="Overall Survival Probability", main.title="Overall Survival\n Conventional Prognostic Factors including 
GTV and QIFs", leg.pos= "topright", leg.text=paste(c("Lowest Risk     ","Low/Medium Risk       ","Medium Risk     
","Medium/High Risk      ","Highest Risk     ")),leg.inset=0, .col=c("black","darkgray"),.lty=c(1,1,3,3,4),.lwd = 
c(4,5,5,5,6), show.n.risk=TRUE, n.risk.step=6, xlim = c(0,42),verbose=TRUE) 
 
###Plot of generated c-indices### 
plot(cindex_clin[1:5,1],cindex_clin[1:5,2],lty = 2,lwd = 3,type="b",pch = 16, cex = 1.5, main = "Time Based 
Concordance Index\n Clinical Penalized CV",xlab="Minimum Time Difference for Patient-Patient Comparison 
(Months)",ylab="C-Index",xaxt="n",ylim = c(0,1)) 
lines(cindex_all[1:5,1],cindex_all[1:5,2],type="b",lty = 1,lwd = 3,pch = 16,cex = 1.5, main = "Time Based 
Concordance Index\n Clinical + QIF Penalized CV",xlab="Minimum Time Difference for Patient-Patient 
Comparison (Months)",ylab="C-Index",xaxt="n",ylim = c(0,1)) 
legend("topright",c("CPFs including GTV & QIFs","CPFs including GTV","CPFs excluding GTV"),lty = 
c(1,2,3),lwd = 3,cex=1.5) 
axis(side = 1,at = seq(0,48,6)) 
 
###Identification of covariates selected in >50% of CV folds### 
cnames<-table(termsOPTouter_clin)[order(table(termsOPTouter_clin))] 
anames<-table(termsOPTouter_all)[order(table(termsOPTouter_all))] 
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clinvars<-cnames[which(cnames>length(out_stat)*0.5)] 
allvars<-anames[which(anames>length(out_stat)*0.5)] 
 
###development of "final" models### 
clinform<-as.formula(paste("Surv(","out_time,","out_stat",")~",paste(names(clinvars),collapse="+"),sep = '')) 
allform<-as.formula(paste("Surv(","out_time,","out_stat",")~",paste(c(names(allvars),"Overall"),collapse="+"),sep 
= '')) 
 
###Likelihood ratio test comparing models (need to be nested)### 
anova(coxph(clinform,data=data),coxph(allform,data=data)) 
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Appendix D: Relationship of Cardiothoracic Dosimetry with Disease Solidity 
 
The delivered radiation therapy treatment plans for patients in Cohort 3 were retrospectively 
analyzed. Treatment planning contours were used to determine the mean lung dose, V20 (percent of the 
total volume of lung receiving 20 Gy), and the mean heart. We were able to obtain these metrics for 
193/195 patients for mean lung dose and V20 and 190/195 patients for mean heart dose. Solidity was 
calculated on each patient’s pretreatment FDG-PET using the primary and nodal tumor contours as 
previously described (3.5 Region of Interest Contouring on PET). We hypothesized that dispersed disease 
(i.e. low values of solidity) would increase the dose delivered to cardiothoracic normal tissues.  
Scatter plots were generated comparing GTV versus solidity in terms of mean lung dose, V20, 
and mean heart dose (Figure 39, Figure 40, and Figure 41, respectively). The first and third quartiles of 
the dosimetric variables were used as cutoffs for categorizing the value as low, medium, or high.  This 
categorization was illustrated by the different point colors within the generated scatter plots.  
 
Figure 39. GTV versus solidity in terms of mean lung dose 
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Figure 40. GTV versus solidity in terms of lung V20 
 
Figure 41. GTV versus solidity in terms of mean heart dose 
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For both the mean lung dose and V20, it can be qualitatively observed that patients in the upper 
quartile (red) are those with large volume and low solidity and those in the lower quartile (green) are 
those with low volume and high solidity. This pattern is not observed to the same extent in regard to mean 
heart dose. This is probably due to the increased importance of proximity to the heart which was not taken 
into account.  
Boxplots were also generated using a risk score (Figure 42, Figure 43, Figure 44). Patients with a 
GTV greater than the median and a solidity value less than the median were assigned a score of 2, patients 
with either a GTV greater than the median or a solidity value less than the median were assigned a score 
of 1, and those with a GTV less than the median and a solidity value greater than the median were 
assigned a score of 0. Generally, patients with large AND dispersed disease were given a score of two, 
patient with either larger OR dispersed disease were given a score of one, and those with smaller, 
compact disease were given a score of zero. This was performed for mean lung dose, V20, and mean 
heart dose. Differences in values between risk score groups were assessed using unpaired t-tests.   
 
Figure 42. Mean lung dose stratified by risk score 
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Figure 43. Lung V20 stratified by risk score 
 
Figure 44. Mean heart dose stratified by risk score 
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For mean lung dose and V20, significant differences (p < 0.05) were seen between all three risk 
score groups. For mean heart dose, there was a significant difference between patients with risk scores of 
0 versus 1, but there was no statistically significant difference between patients with risk scores of 1 
versus 2.  
Lastly, we generated linear regression models relating solidity to mean lung dose, V20, and mean 
heart dose while controlling for GTV. The p-values for decreasing solidity leading to an increase in 
cardiothoracic dosimetry values while controlling for GTV in the regression models were 2.5x10-9, 
2.8x10-11, and 0.002 for mean lung dose, V20, and mean heart dose, respectively. Solidity is therefore 
considered to be an independent predictor of all three cardiothoracic dosimetry values even when 
controlling for the volume of disease. This confirmed our hypothesis that more dispersed disease would 
increase the dose to cardiothoracic normal tissues.  
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Appendix E: Comparison of FDG-PET Delineation Methods 
A variety of methods exist for delineating tumors on FDG-PET. We examined common semi-
automatic methodologies (SUV≥2.5, 40% SUVmax, 50% SUVmax) and compared the values obtained 
terms of volume, uniformity, COM energy, and SUVmean compared to the PETedge method used in our 
work using the concordance correlation coefficient (CCC). We examined 20 patients with a volume 
distribution similar to our entire 195 patient cohort in terms of range and median/mean of tumor volumes. 
A summary table of the CCC values is shown below. 
Table 22. CCC Values for Comparison of Delineation Methodologies  
 Volume Uniformity COM Energy SUVmean 
SUV≥2.5 0.89 0.91 0.94 0.7 
40% SUVmax 0.82 0.77 0.77 0.88 
50% SUVmax 0.65 0.64 0.75 0.78 
 
It was observed that delineating using SUV≥2.5 consistently overestimated the volume of the 
tumors and underestimated the SUVmean compared with when PETEdge was used. Delineating using 
40% and 50% SUVmax consistently underestimated the tumor volume, overestimated the uniformity (in 
terms of uniformity and COM energy) and overestimated the SUVmean. The analyzed segmentation 
methods all yielded reasonably different results than those obtained by PETedge for the assessed metrics 
(volume, uniformity, COM energy, and SUVmean). Furthermore, these segmentation methods may also 
have overly optimistic results due to the caveats described below.  
There are some caveats to this analysis. First, I generated not only the PETedge contours but also 
the other contours from various delineation methods. While semi-automatic, the other methods are still 
very reliant on the bounding box applied. Since I had a general notion of the contour result from 
PETedge, I may have biased the size and location of the bounding box to tightly conform to what I 
believed the contour should look like based on PETedge. Furthermore, MIMvista automatically adjusts 
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the window/level of the images based on the values within the image and therefore may result in more 
consistent values than software this feature is not available and the window/level settings are more user 
dependent. Overall, the results may overestimate the accuracy of these methods due to the caveats 
mentioned. There is substantial evidence in the literature regarding the insufficiencies of the methods 
tested.42, 67–69 
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Appendix F: Sequential FDG-PET Analysis 
Ninety seven patients at the time of analysis were enrolled in a protocol entitled “A Bayesian 
Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, with Concurrent 
Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma”. Patients were excluded for 
small  (<5cc) initial primary tumor volume, if they did not have an FDG-PET scan taken either during 
treatment (~30 days from initiation) or post treatment, or if their scans were performed with 2D 
reconstruction. We wanted to assess whether we would be able to observe changes in QIFs across 
different time points. Having only twenty two patient did not really allow for us to sufficiently correlate 
changes in QIFs with any outcomes. In general, it was observed that tumors decreased in volume, 
SUVmax, and SUVmean while becoming more uniform in terms of uniformity and COM energy (see 
Figures, below).  
 
 
Figure 45. Primary volume changes during treatment 
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 Figure 46. SUVmax changes during treatment 
 
Figure 47. SUVmean changes during treatment 
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Figure 48. Uniformity changes during treatment 
 
Figure 49. COM Energy changes during treatment 
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 A summary of the primary tumor feature changes from pre to mid treatment and pre to post 
treatment are shown in Table 23.  
Table 23. Summary of Changes in Features between Pre, Mid, and Post Treatment  
Feature Average 
Pre-
Treatment 
Average 
Mid-
Treatment 
Average 
Post-
Treatment 
Average % 
Change Pre to 
Mid 
Average % 
Change Pre to 
Post 
Volume (cc) 56.5 39.9 16.0 -114 -2077 
SUVmax 16.9 9.0 5.5 -117 -223 
SUVmean 8.9 4.6 3.8 -127 -161 
Uniformity 0.11 0.25 0.43 46 70 
COM energy 0.02 0.12 0.20 62 87 
 
 Table 23 shows that tumors became smaller, less FDG-avid (in both max and mean SUV), and 
more homogeneous (in terms of uniformity and COM energy) from pre-treatment to mid-treatment as 
well as pre-treatment to post treatment. The volume, SUVmax and SUVmean decreased on average by 
approximately 110-130 percent while uniformity and COM energy increased by approximately 50 percent 
from pre-treatment to post treatment. These trends increased from pre-treatment to post treatment with 
even larger reductions in primary volume, SUVmax, and SUVmean and increases in uniformity and COM 
energy. These analysis are inherently selecting tumor that do not have a complete response mid or post 
treatment as lesions would not be evaluable for quantitative analysis. Therefore, this type of assessment 
may be useful in characterizing lesions with a partial response, stable disease, or progressive disease. 
Quantifying changes in tumor uniformity during treatment alongside changes in volume and FDG-avidity 
may provide complimentary information that may be useful assessing response to therapy. Larger 
analyses would be needed to generate evidence relating changes in tumor uniformity to response or 
patient outcome.  
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Appendix G: Assessment of Volumetric Stability 
Primary tumors from FDG-PET scans in cohort 5 were used to determine volumetric stability (i.e. 
reproducibility of QIFs across changes in tumor volume) via resampling (3.7.7 Analysis of PET Tumor 
Resampling (Cohort 5)).  An example using histogram entropy is shown in Figure 50. Figure 50A-E show 
plots of the resampled entropy values versus the original entropy values with the corresponding CCC. 
Figure 16F displays a plot of the CCC values with respect to the approximate number of voxels. Table 24 
contains the CCC values for a variety of features and their association with the number of voxels post 
resampling. It can be observed that the reproducibility decreases as the number of voxels post resampling 
is reduced. Certain features such as mean and standard deviation are stable regardless of the number of 
voxels while other features degrade by varying amounts as the number of voxels is reduced.    
   
Figure 50. Plots of original versus resampled entropy values and associated CCC values 
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Table 24. CCC values of features with respect to the resampled number of voxels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Voxel Number Groups 
QIFs 27 55 108 226 488 
Volume 0.92 0.94 0.94 0.98 0.99 
cumHistogram 0.35 0.28 0.68 0.67 0.91 
TLG 0.97 0.97 0.98 0.99 0.99 
GlobalEntropy 0.59 0.74 0.87 0.92 0.96 
COV 0.63 0.57 0.79 0.90 0.98 
Global Max 0.73 0.73 0.87 0.88 0.93 
Global Mean 0.98 0.98 0.97 0.98 0.97 
Global Std 0.97 0.94 0.90 0.93 0.96 
Global Uniformity 0.63 0.76 0.89 0.93 0.97 
Kurtosis 0.43 0.49 0.52 0.80 0.91 
Skewness 0.61 0.46 0.78 0.92 0.97 
COM Contrast 0.48 0.59 0.76 0.85 0.94 
COM Correlation 0.04 0.03 0.05 0.11 0.28 
COM Energy 0.62 0.86 0.97 0.99 0.99 
COM Homogeneity 0.56 0.73 0.73 0.86 0.93 
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A volume threshold below which quantitative features cannot be accurately/reproducibility 
measured is an area that requires further investigation. A couple publications have examined this issue but 
a consensus on size limitation has not been reached in order to ensure adequate sampling.53, 70 We found 
that features from tumors consisting of ~55 voxels (~5cc) yielded similar feature reproducibility to much 
larger lesions and that reproducibility suffers when resampling the same tumors to a smaller size. While 
improving reproducibility across tumor volumes is important it is not the only factor one should consider. 
Excluding larger and larger tumors due to non-ideal reproducibility also means reducing cohort sizes and 
the general applicability of quantitative techniques. For example, in our 225 patient cohort with FDG-PET 
scans 93% of patients have primary tumors with at least 27 voxels (lowest cutoff used in analysis). 
However, the percent of eligible patients decreases to 86%, 79%, 61%, and 46% when having a cutoff of 
at least 55, 108, 226, and 488 primary voxels, respectively.  
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